NOVO CONJUGADO DE AMANITINA

A stable amatoxin-anti-BCMA antibody conjugate with a cleavable linker addresses the instability issue of existing constructs, offering improved efficacy in treating multiple myeloma and other cancers.

BR112019012937B1Active Publication Date: 2026-11-10HEIDELBERG PHARMA RES GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
BR112019012937
Authority / Receiving Office
BR · BR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2016-12-23
Filing Date
2017-12-22
Publication Date
2026-11-10
Estimated Expiration
2037-12-22

AI Technical Summary

Technical Problem

Current amatoxin-based antibody drug conjugates are not stable under stress conditions in plasma, leading to substantial cross-linking and reduced efficacy, limiting their therapeutic potential for treating cancers like multiple myeloma.

Method used

A conjugate is developed using a variant form of amatoxin linked to an anti-BCMA antibody via a cleavable linker, specifically with a 6'-deoxy and S-deoxy positions, and a BCMA-linking group with a D265C mutation, enhancing stability and efficacy.

Benefits of technology

The conjugate exhibits increased stability under human plasma conditions and improved therapeutic index, demonstrating enhanced cytotoxicity and antitumor activity against multiple myeloma and other cancers.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

"Novel amatoxin conjugate." The invention relates to a conjugate comprising (a) an amatoxin comprising (i) an amino acid 4 with a 6'-deoxy position; and (ii) an amino acid 8 with an s-deoxy position; (b) a bcma linking group comprising (i) the variable domains of the humanized antibody j22.9-isy, and (ii) a heavy chain constant region comprising a d265c mutation; and (c) a linker that links the amatoxin and said target linking group; furthermore, the invention relates to a pharmaceutical composition that includes such conjugate, namely for use in the treatment of multiple myeloma.
Need to check novelty before this filing date? Find Prior Art

Description

1 / 70 NEW AMANITINA CONJUGATE. FIELD OF THE INVENTION [1] The invention relates to a conjugate comprising (a) an amatoxin comprising (i) an amino acid 4 with a 6'-deoxy position; and (ii) an amino acid 8 with an S-deoxy position; (b) a BCMA linking group comprising (i) the variable domains of the humanized antibody J22.9-ISY, and (ii) a heavy chain constant region comprising a D265C mutation; and (c) a linker that links the amatoxin and said target linking group. Furthermore, the invention relates to a pharmaceutical composition comprising such conjugate, notably for use in the treatment of multiple myeloma. BACKGROUND OF THE INVENTION [2] Multiple myeloma (MM) is the second most prevalent hematopoietic malignancy characterized by the proliferation of a single clone of plasma cells derived from B cells in the bone marrow. MM ranks as the 15th most common type of cancer in the US and is still considered incurable, with a median survival rate of about 30–60 months. Although advances in MM treatment using conventional and novel therapies, alone or in combination, have resulted in improved response rates and therefore prolonged median survival of many years, MM is still considered an incurable disease. MM accounts for about 0.8–1% of all cancers worldwide and approximately 10% of all hematologic cancers, with an estimated global incidence of more than 100,000 new cases per year. Petition 870190057479, dated 06 / 21 / 2019, page 9 / 302 2 / 70 and a global mortality rate of over 70,000 cases annually (SEER database of the National Cancer Institute). [3] Uncontrolled proliferation of plasma cells in MM results in the abnormal production of monoclonal immunoglobulins (also known as M protein) which can lead to renal failure caused by immunoglobulin light chains or hyperviscosity due to excessive amounts of M proteins. In summary, clinically symptomatic MM is characterized by the presence of M protein in serum and / or urine and end organ damage, usually involving hypercalcemia, renal failure, anemia, and bone marrow lesions (characteristics of CRAB) (Bird et al., 2011; Rajkumar et al., 2014). [4] Despite several treatment options, MM is an incurable disease and almost all patients will eventually develop resistant or refractory disease. Relapsed MM refers to progressive disease in which at least a partial response was previously achieved after first-line salvage therapy treatment. Refractory MM indicates progressive disease when the patient does not respond initially or after treatment within the last 60 days (Dimipoulos et al., 2015). [5] Without any treatment, the median survival time after diagnosis of a patient with multiple myeloma is about three years (Kyle and Rajkumar, 2004). There are now several classes of drugs used in the treatment of multiple myeloma: immunomodulatory drugs (thalidomide, lenalidomide, pomalidomide), Petition 870190057479, dated 06 / 21 / 2019, page 10 / 302 3 / 70 proteasome inhibitors (bortezomib, carfilzomib) and stem cell transplantation. Many of the notable drugs in these classes have been approved in the last 10-15 years. Treatments using these newer drugs and chemotherapy in combination with autologous or allogeneic hematopoietic stem cell transplantation (HSCT) have been shown to improve median survival to five years, making this the current standard therapy. However, many patients relapse or develop treatment resistance, leaving a need to develop safe and effective treatments that prolong the duration of remission and improve survival. [6] Approximately 30% of patients with MM will develop renal failure during the course of the disease, and 20% will present with renal failure caused by the accumulation and precipitation of light chains. Renal morbidity is a considerable burden for patients, with an incidence of renal replacement therapy for end-stage renal disease due to MM. New agents such as the proteasome inhibitor bortezomib can successfully restore renal function in a considerable proportion of patients, and complications due to renal failure can be avoided when detected and treated early (Dimopoulos et al., 2008). [7] Even though agents such as proteasome inhibitors and / or immunomodulatory drugs have improved patient outcomes, these agents do not cure the disease. Thus, the need for new agents with new modes of action remains. Knowledge of Petition 870190057479, dated 06 / 21 / 2019, page 11 / 302 The detection of 4 / 70 molecules expressed on the surface of multiple myeloma cells has resulted in a series of novel monoclonal antibodies currently under development for new therapies. However, most of these molecules are not exclusively expressed on MM cells, and their potential to treat MM needs to be demonstrated. [8] Numerous drugs and therapies are currently in clinical trials: antibodies such as daratumumab targeting CD38 and elotuzumab targeting SLAMF7 (Signaling Lymphocyte Activation Molecule Family Member 7), both used alone or in combination with other drugs; panabinostat, a histone deacetylase (HDAC) inhibitor to be used in combination therapy; chimeric antigen receptor (CAR-T) T cells designed to express a variable single-chain anti-BCMA fragment allowing specific targeting of MM cells. [9] MM is characterized by the malignant proliferation of plasma cells, terminally differentiated B cells that, under normal circumstances, are responsible for the mass production of immunoglobulins. This progression of plasma cells into malignant myeloma cells is associated with multiple genetic and oncogenic events, including dysregulation of cyclin D1 and c-Myc, and mutations such as KRAS, BRAF, FGFR3 (fibroblast growth factor receptor 3) and TP53 (Shaffer et al., 2008; Kuehl and Bergsagel, 2012; Chesi and Bergsagel, 2015).

[10] Despite these genetic changes, the malignant plasma cell remains largely dependent on the bone marrow (BM) environment. Petition 870190057479, dated 06 / 21 / 2019, page 12 / 302 5 / 70 After MM cells bind to BM, signaling cascades are activated, including accessory growth factors and their ligands secreted by accessory BM cells. The components released by these accessory cells play a key role in MM, both in promoting disease and in evading immune surveillance.

[11] Antibody drug conjugates (ADCs) aim to take advantage of the specificity of monoclonal antibodies to deliver potent cytotoxic drugs selectively to tumor cells that present antigens.

[12] The antibody must target a well-characterized antigen, with high and specific expression at the tumor site and low or no expression in normal tissue, thus maximizing the effectiveness of the ADC and limiting toxicity.

[13] Members of the tumor necrosis factor receptor (TNFR) superfamily and their ligands play a critical role in controlling B cell proliferation, differentiation, and apoptosis. In particular, B cell activating factor (BAFF) and its ligand-receptor network play a central role in regulating B cell maturation and differentiation into malignant plasma cells. The functionally related BAFF receptors BAFF-R, cyclophilin ligand interactor (TACI), and B cell maturation antigen (BCMA) are type III transmembrane proteins lacking a signal peptide and containing cysteine-rich extracellular domains.

[14] These receptors promote the survival of B cells in Petition 870190057479, dated 06 / 21 / 2019, page 13 / 302 6 / 70 distinct stages of development and, therefore, their expression patterns in B cells differ depending on the B cell type and its stage of maturation and activation. BAFF-R expression is not detectable in B cell precursors, but it is the dominant receptor expressed in mature B cells. BAFF-R mediates B cell survival, sustains the longevity of the germinal center reaction, and promotes immunoglobulin class recombination. TACI is expressed in both activated B cells and T cells and is important in class switch recombination and supports the T cell-dependent antibody response. BCMA, which is almost exclusively expressed in plasma cells but absent from naive B cells and memory B cells, promotes the differentiation of B cells into plasma cells and thus promotes the maintenance of the humoral immune response.Soluble BCMA is elevated in the serum of MM patients, and successful infusion of donor lymphocytes is associated with the formation of antibodies against BCMA. The serum BCMA level found among MM patients is associated with clinical status and overall survival. (Belucci et al., 2005; Sanchez et al., 2012).

[15] BAFF, APRIL (a proliferation-inducing ligand), and BCMA play critical roles in the decision-making process from the B cell to the plasma and MM cell. As B cells exit the bone marrow, further maturation into marginal zone B cells (MZ B) depends on BAFF. BAFF is also essential for the homeostasis of naive recirculating B cells and MZ B cells. Dysregulation of BAFF-R in plasma cells coincides with the Petition 870190057479, dated 06 / 21 / 2019, page 14 / 302 7 / 70 positive regulation of BCMA, which can bind BAFF and APRIL. The transcription factor NFkB plays a crucial role in regulating pathways, B cell proliferation, survival, and differentiation. NFkB activity is modulated by inhibitors of κB proteins (IkB). Among these, IκBα retains inactive NFkB dimers in the cytoplasm and, when degraded, releases bound NFkB dimers to translocate to the nucleus and gene drive expression. The regulation of IkB activity through degradation depends on serine phosphorylation by IkB kinase (IKK) (Rickert et al., 2011).

[16] Several anti-BCMA antibodies have been generated in the past, including the murine antibody J22.9 (WO 2014 / 068079) and its humanized versions (WO 2015 / 166073).

[17] In order to obtain antibody-drug conjugates, bifunctional ligands with binding sites for both antibodies and drugs are used to link the two components.

[18] With regard to antibody conjugation, ligand binding strategies typically rely on cysteine ​​or lysine residues in the antibody. Ideally, the ligand should remain stable in systemic circulation to minimize adverse or toxic effects. After antigen recognition and binding, the resulting ADC-receptor complex is internalized via receptor-mediated endocytosis. The unconjugated toxin must demonstrate high potency to allow for effective kill after ADC release. The release of the toxic payload should only occur within the target cell, and the ADC should be stable in plasma. For antibody toxin release in Petition 870190057479, dated 06 / 21 / 2019, page 15 / 302 8 / 70 inside cellular ligands, these can be either cleavable (cleaved by lysosomal proteases, hydrolyzed at low pH in the lysosomal compartment, or released from disulfide bonds by intracellular agglutination) or non-cleavable (depending on the complete degradation of the antibody after internalization of the ADC).

[19] Finally, with regard to the toxic payload of antibody drug conjugates, two main classes of cytotoxic agents are currently used in clinical assessments: drugs that disrupt microtubule assembly or compounds that bind to the minor groove of DNA, causing double-strand breaks.

[20] Amatoxins are cyclic peptides composed of 8 amino acids found in the mushrooms Amanita phalloides (see figure 1). Amatoxins specifically inhibit DNA-dependent RNA polymerase II in mammalian cells and, consequently, also the transcription and protein biosynthesis of the affected cells. Inhibition of transcription in a cell causes growth and proliferation arrest. Although not covalently linked, the complex between amanitin and RNA polymerase II is very tight (KD = 3 nM). The dissociation of amanitin from the enzyme is a very slow process, thus making recovery of an affected cell unlikely. When transcription inhibition lasts for a long time, the cell will undergo programmed cell death (apoptosis).

[21] The use of amatoxins as cytotoxic groups for tumor therapy had already been explored in 1981, by coupling an anti-Thy 1.2 α-amanitin antibody using a ligand linked to the indole ring of Petition 870190057479, dated 06 / 21 / 2019, page 16 / 302 9 / 70 Trp (amino acid 4; see Fig. 1) via diazotization (Davis & Preston, Science 213 (1981) 1385-1388). Davis & Preston identified the attachment site as position 7'. Morris & Venton also demonstrated that substitution at position 7' ​​results in a derivative that maintains cytotoxic activity (Morris & Venton, Int. J. Peptide Protein Res. 21 (1983) 419-430).

[22] Patent application EP 1 859 811 A1 (published on November 28, 2007) described conjugates in which the γ-C atom of the amino acid amatoxin 1 of β-amanitin was directly coupled, i.e., without a linking structure, to albumin or to the monoclonal antibody HEA125, OKT3 or PA-1. In addition, the inhibitory effect of these conjugates on the proliferation of breast cancer cells (MCF-7), Burkitt lymphoma cells (Raji) and T lymphoma cells (Jurkat) was demonstrated. The use of ligands was suggested, including ligands that include elements such as amide, ester, ether, thioether, disulfide, urea, thiourea, hydrocarbon molecules and the like, but no linking element was presented, nor were further details provided, such as binding sites on amatoxins.

[23] Patent applications WO 2010 / 115629 and WO 2010 / 115630 (both published on October 14, 2010) describe conjugates wherein antibodies, such as anti-EpCAM antibodies, such as humanized antibodies huHEA125, are associated with amatoxins via: i) the γ-C atom of amino acid amatoxin 1, ii) the 6'-C atom of amino acid amatoxin 4, or iii) the δ-C atom of amatoxin 3, in each case directly or via a linker between the antibody and the Petition 870190057479, dated 06 / 21 / 2019, page 17 / 302 10 / 70 amatoxins. Suggested ligands include elements such as amide, ester, ether, thioether, disulfide, urea, thiourea, hydrocarbon fractions, and the like. Furthermore, the inhibitory effects of these conjugates on the proliferation of breast cancer cells (MCF-7 cell line), pancreatic carcinoma (Capan-1 cell line), colon cancer (Colo205 cell line), and cholangiocarcinoma (OZ cell line) have been demonstrated.

[24] It is known that amatoxins are relatively non-toxic when coupled to large biomolecule carriers, such as antibody molecules, and that they exert their cytotoxic activity only after cleavage of the biomolecule carrier. In light of the toxicity of amatoxins, particularly to liver cells, it is extremely important that amatoxin conjugates for targeted tumor therapy remain highly stable after administration into plasma, and that amatoxin release occurs after internalization into target cells. In this context, small improvements in conjugate stability can have drastic consequences for the therapeutic window and safety of amatoxin conjugates for therapeutic approaches.

[25] Patent application WO 2016 / 142049 describes antibody-amanitin conjugates in which the amanitin payload is linked to the antibody via specifically designed cysteine ​​residues in the constant region of the antibody heavy chain. Depending on the nature of the mutated residue, the wild-type amino acid residue substitution can influence activity. Petition 870190057479, dated 06 / 21 / 2019, page 18 / 302 11 / 70

[26] It has already been reported that amatoxin-based antibody conjugates targeting CD269 may offer advantages in the treatment of patients with tumors (see Palfi et al: “Preclinical evaluation of anti-CD269 antibody drug conjugates”, European Journal of Cancer 69 (2016), S21 & 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Munich (Germany) November 29 - December 2, 2016; Palfi et al.: CD269 - A promising target for amanitin-based ADCs, Cancer Research 76 (No. 14 suppl) (2016) 2973 & 107th Annual Meeting of the American Association for Cancer Research, New Orleans (USA) April 16 - April 20, 2016.However, no information was provided regarding the specific nature of the amatoxin derivative used, nor about the specific relationship between this amatoxin derivative and the anti-CD269 antibody.

[27] Thus, significant progress has already been made in the development of amatoxin-based conjugates for therapeutic uses. However, the current inventors have found that the α- and β-amatoxin-based constructs were not fully stable under stress conditions in plasma and resulted in a substantial degree of cross-linked products (see Figure 2). This effect was completely unexpected, and the reasons for this Petition 870190057479, dated 06 / 21 / 2019, page 19 / 302 12 / 70 instability and cross-linking were unclear. Figure 2 further shows that the amount of crosslinked products formed from an amatoxin-based antibody conjugate can be reduced by the addition of cysteine, and Figures 3 and 4 show that α-amanitin reacts with cysteine. However, the stability of conjugates containing a highly toxic amatoxin is of paramount importance for their intended use as a therapeutic molecule for administration to humans. OBJECT OF THE INVENTION

[28] Thus, there was still a great need for amatoxin-based antibody drug conjugates with high efficacy in target cells, and simultaneously with high stability. The solution to this problem, namely, the identification of a) a suitable parental anti-BCMA antibody, b) a suitable strategy for fixing the toxic payload via a ligand to the antibody, c) a suitable ligand and d) a suitable amatoxin variant, was neither provided nor suggested by the prior art. SUMMARY OF THE INVENTION

[29] The present invention is based on the unexpected observation that a variant form of amatoxin conjugated to an antiBCMA antibody based on antibody J22.9, in which the antibody and amatoxin are linked by a cleavable linker, exhibits increased stability under stress conditions, namely in human plasma, and an improved therapeutic index.

[30] Thus, in one aspect, the present invention relates to a coupling, according to Formula I, comprising: a) a Petition 870190057479, dated 06 / 21 / 2019, p. 20 / 302 13 / 70 amatoxin comprising: (i) an amino acid 4 with a 6'-deoxy position; and (ii) an amino acid 8 with an S-deoxy position; (b) a BCMA-linking group comprising: (i) the variable domains of the heavy chain according to SEQ ID No. 1 and the light chain according to SEQ ID No. 2 of the J22.9-ISY antibody, and (ii) a constant region of the heavy chain comprising a D265C mutation; and (c) a protease-binding linker, wherein said BCMA-linking moiety is linked to said linker via the thiol group of the modified cysteine ​​residue at position 265 of the antibody heavy chain. Formula 1

[31] In a second aspect, the present invention relates to a pharmaceutical composition comprising the conjugate of the present invention.

[32] In a third aspect, the present invention relates to the conjugate of the present invention, or to the pharmaceutical composition of the present invention, for use in the treatment of cancer in a patient, particularly when the cancer is selected from the group Petition 870190057479, dated 06 / 21 / 2019, page 21 / 302 14 / 70 consisting of multiple myeloma, diffuse large B-cell lymphoma (DLBCL), and chronic lymphocytic leukemia (CLL), particularly multiple myeloma. BRIEF DESCRIPTION OF THE FIGURES

[33] Fig. 1 shows the structural formulas of different amatoxins. The numbers in bold (1 to 8) designate the standard numbering of the eight amino acids that form amatoxin. The standardized designations of the atoms of amino acids 1, 3 and 4 are also indicated (Greek letters α to γ, Greek letters α to δ and numbers 1' to 7', respectively).

[34] Fig. 2 shows the results of a stress test on a Western anti-amanitin blot. A trastuzumabamanitin conjugate (Her-30.0643; 6'-OH lysine conjugate; stable ligand) was incubated for 5 days at 37°C in PBS, pH 7.4, which led to extensive inter- and intra-chain crosslinking; antibody chain crosslinking could be reduced by the addition of free cysteine.

[35] Fig. 3 shows α-amanitin shows a strong reactivity with cysteine ​​in PBS buffer, pH 7.4. 1 mg / mL α-amanitin 10 mg / mL cysteine ​​in PBS, pH 7.4 at 37°C after 24 h, 48 h and 6 d RP-HPLC C18.

[36] Fig. 4 shows β-amanitin shows a strong reactivity with cysteine ​​in PBS buffer, pH 7.4. 1 mg / mL β-amanitin 10 mg / mL cysteine ​​in PBS, pH 7.4 at 37°C after 24 h, 48 h and 6 d RP-HPLC C18.

[37] Fig. 5 shows that a 6'-deoxy variant in amino acid 4 (amanine) shows reduced reactivity with cysteine. 1 mg / mL amanine 10 mg / mL cysteine ​​in PBS, pH 7.4 at 37°C after 24 h, 48 h Petition 870190057479, dated 06 / 21 / 2019, page 22 / 302 15 / 70 d RP-HPLC C18.

[38] Fig. 6 shows that a double variant of deoxy HDP 30.2105 (6'-deoxy at amino acid 4 and S-deoxy at amino acid 8; formula I with R3= -OR5 and each R5= H) shows complete absence of reactivity with cysteine. 1 mg / mL of HDP 30.2105, 10 mg / mL of cysteine ​​in PBS, pH 7.4 at 37°C after 24 h, 48 h and 6 d RP-HPLC C18; * impurity.

[39] Fig. 7 summarizes the results of Figures 3 to 6; x-axis: reaction time in hours; y-axis: amount of remaining amatoxin variant in %.

[40] Fig. 8 shows the alpha-amanitin derivative HDP 30.1699 with cleavable ligand in the AA4 - 6-OH moiety, the alpha-amanitin derivative HDP 30.2060 with cleavable ligand in the γ-position AA1 and the double deoxy amatoxin variant HDP 30.2115 with cleavable ligand in the γ-position AA1.

[41] Fig. 9 shows the Western blot analysis of amatoxin derivatives HDP 30.1699, HDP 30.2060 and HDP 30.2115 conjugated to reference the Thiomab antibody with the D265C mutation after incubation at 37°C in human plasma, rat plasma and phosphate buffer solution (PBS) for 0, 4 and 10 days. Detection was performed with rabbit polyclonal anti-amanitin antibody and horseradish peroxidase-conjugated anti-rabbit antibody. HDP 30.1699 and HDP 30.2060 showed considerable cross-linking and loss of the amatoxin fraction. The HDP 30.2115 variant of the double deoxidizing amanitin exhibits high stability and significantly reduced cross-linking.

[42] Fig. 10 shows the cytotoxicity of the derivatives of Petition 870190057479, dated 06 / 21 / 2019, page 23 / 302 16 / 70 amatoxin HDP 30.1699, HDP 30.2060, and HDP 30.2115 conjugates to the Thiomab reference antibody with the D265C mutation. Test items were incubated in human plasma at 37°C for 0 to 4 days. The cytotoxicity assay was performed in SKBR-3 cells for 96 h. HDP 30.1699 and HDP 30.2060-based ADCs show notable loss of cytotoxicity after 4 days of plasma stress, while the deoxygenated derivative HDP 30.2115 still shows picomolar activity.

[43] Fig. 11 shows the cytotoxicity of amatoxin derivatives HDP 30.1699, HDP 30.2060 and HDP 30.2115 conjugated to Thiomab reference antibody with D265C mutation. Test items were incubated in rat plasma at 37°C for 0 to 4 days. The cytotoxicity assay was performed in SKBR-3 cells for 96 h. HDP 30.1699 and HDP 30.2060 ADCs show notable loss of cytotoxicity after plasma stress, while the deoxygenated derivative HDP 30.2115 remains almost unchanged.

[44] Fig. 12 shows the cytotoxicity of amatoxin derivatives HDP 30.1699, HDP 30.2060 and HDP 30.2115 conjugated to Thiomab reference antibody with D265C mutation. Test items were incubated in PBS at 37°C for 0 to 4 days. The cytotoxicity assay was performed on SKBR-3 cells for 96 h. All ADCs show adequate stability in the non-enzymatic environment.

[45] Fig. 13 compares the antitumor activity of different amatoxin conjugates based on a tumor-targeted reference antibody (HDPref) - in a xenograft model - experiment Petition 870190057479, dated 06 / 21 / 2019, page 24 / 302 17 / 70 single dose. Depending on the ligand and toxin structure, significant differences in antitumor activity have been observed. The deoxy-amanine variant HDPref-30.2115 (6'-deoxy at amino acid 4 and S-deoxy at amino acid 8) showed better antitumor activity than all amatoxin ADCs, with a significantly better therapeutic index than the corresponding cleavable ligand ADC HDPref-30.1699 (lysine conjugation via 6'-OH; S=O at amino acid 8).

[46] Fig. 14 shows the Kaplan-Meier survival analysis in a systemic tumor model - single-dose experiment with reference antibodies. In summary, 2.5x106 tumor cells in 200 pL PBS / mouse were inoculated intravenously on day 0. Therapy (single dose, iv) was initiated on the third day after inoculation of the tumor cells. The deoxyamanine variant HDPref-30.2115 (6Z-deoxy at amino acid 4 and S-deoxy at amino acid 8) showed superior survival to HDPref-based conjugates with β-amanitin derivatives HDP 30.1699, HDP 30.0880 and HDP 30.0643 as well as the corresponding MMAE derivative.

[47] Fig. 15 shows that J22.9-ISY and thiomab J22.9-ISY-D265C have binding properties comparable to BCMA-positive cells. Flow cytometry binding assay results of the J22.9-ISY and J22.9-ISY-D265C antibody variants revealed binding properties comparable to BCMA-expressing MM.1S Luc and NCIH929 cells.

[48] ​​Fig. 16 shows the QA results of the production of (A) J22.9-ISY-D265C-30.2115, and (B) J22.9-ISY-D265C-30.1699. Petition 870190057479, dated 06 / 21 / 2019, page 25 / 302 18 / 70

[49] Fig. 17 shows the results of the stability experiments: J22.9-ISY-D265C-30.2115 (A) and J22.9-ISY-D265C30.1699 (B) were incubated in humans, cynomolgus, or rat plasma or PBS for control for 0, 4, and 10 days at 37°C and analyzed by SDS-PAGE reduction and subsequent anti-amanitin Western Blot.

[50] Fig. 18 shows the results of experiments analyzing plasma stability and cytotoxic potential. J22.9ISY-D265C-30.2115 (A) and J22.9-ISY-D265C-30.1699 (B) were incubated in PBS for control, or human, cynomolgus or mouse plasma for 0, 4, and 10 days at 37°C and analyzed for potential remaining cellular toxicity using BCMA-positive NCI-H929 cells.

[51] Fig. 19 shows the BCMA expression levels in different cell lines used for cytotoxicity assays. Western Blot analyses using antibodies against BCMA, CD138, RNA polymerase 2A (POLR2A), p53 and GAPDH (control). All cell lines express BCMA, except CCRF-CEM which was a BCMA-negative cell line. The highest BCMA levels are detected in NCI-H929 cells, the lowest in RPMI8226 cells.

[52] Fig. 20 shows the results of the cellular cytotoxicity experiments: The viability of BCMA-positive (NCI-H929, MM.1S, MM.1S Luc, U266B1, OPM-2) and BCMA-negative (CCRF-CEM) cells after incubation for 96 hours with J22.9-ISY-D265C30.1699 and J22.9-ISY-D265C-30.2115 was monitored. Cytotoxicity was calculated as half the maximum effective concentration (EC50). Petition 870190057479, dated 06 / 21 / 2019, page 26 / 302 19 / 70

[53] Fig. 21 shows antitumor activity in subcutaneous xenograft of NCI-H929 mice in single-dose application: Female CB-17 Scid mutant mice were subcutaneously inoculated with 5x106 NCI-H929 cells. When the tumor volume reached 80 mm3, the mice (8 animals per group) were intravenously treated with single doses (2 or 4 mg / kg) of J22.9ISY-D265C-30.2115 or J22.9-ISY-D265C-30.1699, or treated with PBS as a control. Tumor volumes were monitored twice weekly.

[54] Fig. 22 shows antitumor activity in subcutaneous xenograft of NCI-H929 mice in repeated dose application: Female CB-17 Scid mutant mice were subcutaneously inoculated with 5x106 NCI-H929 cells. When the tumor volume reached 80 mm3, the mice (9 animals per group) were treated intravenously once a week (1x / week), every two weeks (1x / 2 weeks) or every 3 weeks (1x / 3 weeks) with J22.9-ISY-D265C-30.2115 (doses of 0.25 mg / kg, 0.5 mg / kg or 1 mg / kg) or treated with PBS as a control. In addition, doses of 2 mg / kg were applied twice a week (2x / week). Tumor volumes were monitored twice a week.

[55] Fig. 23 shows the antitumor activity in the dissemination of the MM.1S Luc xenograft model: (A) Female mice with beige IDCG were intravenously injected with 1x107MM.1S Luc cells. Upon reaching a mean flow of 1.5x106 - 1x107 (10-14 days post-implantation), 8-10 mice per group were treated with doses Petition 870190057479, dated 06 / 21 / 2019, page 27 / 302 (A) Single 20 / 70 doses (2 and 4 mg / kg) of J22.9-ISY-D265C-30.1699, J22.9-ISY-D265C30.2115, or PBS as a control. Luciferase activity was monitored by non-invasive bioimaging twice weekly, 10 minutes after luciferin administration (10 μL / g body weight). (B) Individual tumor growth curves are shown for each animal. Individual growth curves are shown for groups treated with 2 mg / kg (solid line) and 4 mg / kg (dashed line) of J22.9-ISY-D265C-30.2115. Data indicate that only one animal from each group depicted shows elevated tumor signs significantly above the background level.

[56] Fig. 24 shows the antitumor activity in a disseminating MM.1S Luc xenograft model: dose reduction: (A) Female mice with beige IDCG were intravenously injected with 1x107MM.1S Luc cells. Upon reaching a mean flow rate of 1.5x1061x107 (10-14 days post-implantation), 8-10 mice per group were treated with single doses (0.1, 0.3, 1 and 2 mg / kg) of J22,9ISY-D265C-30,2115 or PBS as a control. Luciferase activity was monitored by non-invasive bioimaging twice weekly, 10 minutes after luciferin administration (10 μl / g body weight). (B) Individual tumor growth curves are shown for each animal. Growth curves are shown for groups treated with 1 mg / kg (solid line) and 2 mg / kg (dashed line) of J22.9-ISY-D265C-30.2115. The data indicate that only one animal from each group depicted shows elevated tumor signs significantly above the background level.

[57] Fig. 25 shows the results of a study of Petition 870190057479, dated 06 / 21 / 2019, page 28 / 302 21 / 70 Tolerability in cynomolgus monkeys: Groups of 3 animals were injected with J22.9-ISY-D265C-30.2115 or J22.9-ISY-D265C-30.1699 in escalating doses (0.3, 1 and 3 mg / kg), followed by a repeated dose of 3 mg / kg. ALT: alanine transaminase; AST: aspartate transaminase; LDH: lactate dehydrogenase.

[58] Fig. 26 shows a comparison of the cytotoxic potential of J22.9-ISY-D265C-30.2115 (·) with the monomethyl auristatin F derivative J22.9-ISY-MMAF () in MM.1S Luc (left panel) and KMS-11 cells (right panel): (A) comparison at the 96 h time point, EC50 of J22.9-ISY-D265C-30.2115: 5.575 10-10 M in MM.1S Luc cells; 1.716 10-9 M in KMS-11 cells; EC50 of J22.9-ISY-MMAF: 4.812 10-10 M in MM.1S Luc cells; 6.261 10-10 M in KMS-11 cells; (B) 24-120 h duration of cytotoxic potential in MM.1S Luc cells (J22.9ISY-D265C-30.2115: ·; J22.9-ISY-MMAF: ); (C) 24-120 h time course of cytotoxic potential in KMS-11 cells (J22.9-ISYD265C-30.2115: •; J22.9-ISY-MMAF: ).

[59] Fig. 27 shows the results of a study of the efficacy of J22.9-ISY-D265C-30.2115 compared with the monomethyl auristatin F derivative J22.9-ISY-MMAF and Carfilzomib in a disseminating xenograft model (MM.1S Luc). DETAILED DESCRIPTION OF THE INVENTION

[60] Before the present invention is described in detail below, it should be understood that this invention is not limited to the specific methodology, protocols and reagents described herein, as these may vary. It should also be understood that the terminology used herein is intended to describe only Petition 870190057479, dated 06 / 21 / 2019, p. 29 / 302 22 / 70 particular incorporations, and is not intended to limit the scope of the present invention, which will be limited only by the appended claims. Unless otherwise defined, all technical and scientific terms used herein have the same meanings as are commonly understood by a person skilled in the art.

[61] In particular, the terms used here are defined as described in A Multilingual Glossary of Biotechnological Terms: (IUPAC Recommendations), Leuenberger, HGW, Nagel, B. and Kolbl, H. eds. (1995), Helvetica Chimica Acta, CH-4010 Basel, Switzerland).

[62] Throughout this specification and the claims that follow, unless the context requires otherwise, the word "comprise," and variations such as "comprise" and "comprise," will be understood as implying the inclusion of an integer, composition or step or group of integers or steps, whereas any additional integers, compositions or steps or group of integers, compositions or steps may optionally also be present, including incorporations, where additional integers, compositions or steps or group of integers, compositions or steps are not present. In these latter incorporations, the term "comprise" is used together with "characterized by."

[63] Several documents are cited throughout the text of this specification document. Each of the documents cited here (including all patents, patent applications, scientific publications, manufacturer specifications, instructions, submissions Petition 870190057479, dated 06 / 21 / 2019, p. 30 / 302 23 / 70 of GenBank accession number sequences, etc.), above or below, is incorporated herein by reference in its entirety, to the extent permitted under the respective patent law.

[64] The present invention will now be described in more detail. In the following passages, different aspects of the invention are defined in more detail. Each aspect thus defined can be combined with any other aspect or aspects, unless expressly indicated otherwise. In particular, any feature indicated as being of particular relevance or advantage can be combined with any other feature or features indicated as being of particular relevance or advantage.

[65] The present invention is based on a combination of different advantageous elements and features and, in particular, on the unexpected observation that a variant form of amatoxin conjugated with an anti-BCMA antibody based on antibody J22.9, in which the antibody and amatoxin are linked by a cleavable linker, reveals increased stability under stress conditions, particularly in human plasma, and an improved therapeutic index.

[66] Thus, in one aspect, the present invention relates to a conjugate comprising (a) an amatoxin comprising (i) an amino acid 4 with a 6'-deoxygenating position; and (ii) an amino acid 8 with an S-deoxygenating position; (b) a BCMA linking group comprising the variable domains of the heavy chain according to SEQ ID No. 1 and the light chain according to SEQ ID No. 2 of the J22.9-ISY antibody, and (c) a Petition 870190057479, dated 06 / 21 / 2019, p. 31 / 302, a protease-linked ligand, in which the aforementioned BCMA-linking fraction is linked to this ligand through the thiol group of the cysteine ​​residue at position 265 of the antibody heavy chain.

[67] In a particular embodiment, the linking part to BCMA comprises a heavy constant chain region comprising a D265C mutation.

[68] In one particular embodiment, the ligand is a self-immolating ligand.

[69] In a particular embodiment, the conjugate is the Formula 1

[70] In the context of the present invention, the term amatoxin includes all cyclic peptides consisting of 8 amino acids isolated from the genus Amanita and described in Wieland, T. and Faulstich H. (1978), which comprise the specific positions according to Petition 870190057479, dated 06 / 21 / 2019, p. 32 / 302 25 / 70 i) (i.e., wherein the indole moiety of the tryptophan amino acid residue does not contain an oxygen substitute at the 6' position, especially when the 6' position contains a hydrogen atom) and ii) (i.e., wherein the thioether-sulfoxide moiety of natural amatoxins is replaced by a sulfide), including, moreover, all their chemical derivatives; moreover, all their semi-synthetic analogues; moreover, all synthetic analogues derived from them constructed from building blocks according to the main structure of the natural compounds (cyclic, 8 amino acids); moreover, all synthetic or semi-synthetic analogues containing non-hydroxylated amino acids instead of hydroxylated amino acids; moreover, all synthetic or semi-synthetic analogues, in which case any of these derivatives or analogues exhibits at least the aforementioned positions i) and ii) and is functionally active in inhibiting mammalian RNA polymerase II.

[71] Functionally, amatoxins are defined as peptides or depsipeptides that inhibit mammalian RNA polymerase II. Preferred amatoxins are those having a functional group (e.g., a carboxylic group or a carboxylic acid derivative, such as a carboxamide or a hydroxamic acid, an amino group, a hydroxyl group, a thiol, or a thiol-catching group) that can be reacted with binding molecules or target-fixing groups, as defined above. Amatoxins particularly suitable for the conjugation of the present invention are the di-deoxin variants of α-amanitin, β-amanitin, γ Petition 870190057479, dated 06 / 21 / 2019, page 33 / 302 26 / 70 amanitin, ε-amanitin, amanullinin, amanulinic acid or mono-deoxin variants of amanin, amaninamide, γ-amaninamide or γ-amaninamide, as indicated in Figure 1, as well as salts, chemical derivatives, semi-synthetic analogues and their synthetic analogues.

[72] A variant of amatoxin comprising (i) an amino acid 4 with a 6'-deoxygenating position; and (ii) an amino acid 8 with an S-deoxygenating position was first mentioned in Zhou et al., ChemBioChem 16 (2015) 1420-1425, as one of four diastereomers being obtained in a total synthesis approach for amatoxins. However, the fact that such variants are more stable under stress conditions in plasma and result in a reduced degree of crosslinked products (as shown in Figure 2) was not publicly known at the effective filing date of the present application in December 2016 (see patent application WO 2017 / 149077 published on September 8, 2017).

[73] In a particular embodiment, the conjugate of the present invention has a purity greater than 90%, particularly greater than 95%.

[74] The J22.9 murine monoclonal antibody was obtained using standard hybridoma technology from C57BL / 6 mice immunized with the purified human BCMA extracellular domain (residue 1-54) N-terminally fused to glutathione S-transferase (GST). Due to the instability of hybridomas, variable regions of the light and heavy chains were amplified and cloned upstream of the human kappa constant domain and IgG1, respectively, resulting in Petition 870190057479, dated 06 / 21 / 2019, page 34 / 302 27 / 70 chimeric antibody J22.9-xi (Oden et al., 2015).

[75] The J22.9-xi antibody was humanized based on sequence alignments and data obtained from the crystal structure in order to identify mutations that would potentially disrupt BCMA binding. Briefly, the J22.9-xi Fab fragment was generated from full-length antibody by incubation with pepsin and combined with 54 purified amino acid residues from the BCMA extracellular domain. The isolated complexes were used for crystallization studies and the J22.9-xi BCMA binding epitopes were analyzed in detail (WO2014 / 068079, WO2015 / 166073, Oden et al., 2015, Marino et al. 2016).

[76] Based on these analyses, several combinations of fully humanized gene cassettes were identified and expressed as full-length antibodies. J22.9-H is the fully humanized version of J22.9-xi. J22.9-ISY and J22.9-FSY are fully humanized versions containing, in addition, mutations designed to remove potentially harmful post-translational modification (PTM) motifs.

[77] J22.9-xi binds to purified BCMA and also detects BCMA in the MM.1S, NCI-H929, OPM-2, and RPMI-8226 cell lines. No binding was detected in BCMA-negative cells. Furthermore, flow cytometry analyses revealed that bone marrow cells from MM patients were detectable using J22.9-xi. The affinity of J22.9-xi for BCMA is very high, with a mean Kd of 54 pM, determined by plasmonic resonance (Oden et al., 2015). Petition 870190057479, dated 06 / 21 / 2019, page 35 / 302 28 / 70

[78] BCMA activates nuclear factor B (NFB) pathways and triggers important signals for the survival of MM and plasma cells through interaction with APRIL and / or BAFF. The affinity of J22.9 for BCMA has been shown to be very high and exceeds that of APRIL by 300 times and that of BAFF by 30,000 times (Bossen and Schneider 2006). J22.9-xi efficiently blocks the binding of APRIL and BAFF to BCMA. Furthermore, J22.9-xi interferes with APRIL-induced NFB activation by blocking IB kinase (IKK) phosphorylation and subsequent IB degradation, leading to reduced NFB binding activity to DNA. In summary, J22.9-xi interferes with APRIL-induced NFB activation in BCMA-positive NCI-H929 cells (Oden et al., 2015).

[79] The cytotoxic activity of IgG1 antibodies is achieved through the interaction of IgG1 with the Fc receptor (FcR) on effector cells (e.g., natural killer cells) or with the C1q protein of the complement cascade. This interaction is dependent on the glycosylation of the antibody at the Asn297 position in the constant region of the heavy chain. Glycans in IgG1 exhibit some heterogeneity, but the core structure is generally a fucosylated bi-antenna structure with varying levels of sialic acid in the antennas. Numerous investigations have demonstrated that glycosylation affects binding affinity and the loss of glycosylation completely abolishes binding. The absence of glycosylation disrupts the structural integrity of the Fc region, which is necessary for optimal binding to the Fc receptor (for review, see Hayes et al., 2014). However, the absence of nuclear fucose in IgG results in better binding to the Fc receptor and an increase in cell-dependent cytotoxicity. Petition 870190057479, dated 06 / 21 / 2019, p. 36 / 302 29 / 70 antibodies (ADCC).

[80] Antibody binding to effector or complement cells results in ADCC mediated by natural killer cells or complement-dependent cytotoxicity (CDC). J22.9-xi is capable of inducing strong ADCC and CDC in BCMA-positive MM.1S cells when mixed with the Fc-carrying effector alone, peripheral blood mononuclear cells (PBMCs) from healthy donors.

[81] Chimeric and humanized antibody variants bind to cell lines expressing BCMA. No differences in binding characteristics were observed for J22.9-ISY and J22.9FSY, while the binding affinity of the humanized variant J22.9-H was much lower.

[82] In the context of the present invention, the term purity refers to the total amount of conjugates present. For example, a purity greater than 90% means that, in 1 mg of a composition containing a conjugate of the present invention, that conjugate has more than 90%, i.e., more than 900 pg. The remaining part, i.e., impurities, may include unreacted raw materials and other reagents, solvents, cleavage products and / or by-products.

[83] In a particular embodiment, a composition consisting of a conjugate of the present invention includes more than 100 mg of that conjugate. Thus, trace amounts of a conjugate of the present invention that may be present in complex preparations of conjugates of the prior art, for example, partial reduction of Petition 870190057479, dated 06 / 21 / 2019, p. 37 / 302 30 / 70 natural sulfoxides.

[84] As used herein, a first compound (e.g., an antibody) is considered to bind specifically to a second compound (e.g., an antigen, such as a protein- (target), if it has a dissociation constant KD for that second compound of 100 μM or less, namely 50 μM or less, namely 30 μM or less, namely 20 μM or less, namely 10 pM or less, namely 5 pM or less, namely 1 pM or less, more particularly 900 nM or less, more particularly 800 nM or less, more particularly 700 nM or less, more particularly 600 nM or less, more particularly 500 nM or less, more particularly 400 nM or less, more particularly 300 nM or less, more particularly 200 nM or less, more particularly 100 nM or less, more particularly 90 nM or less, more particularly 80 nM or less, more particularly 70 nM or less, more particularly 60 nM or less, more particularly 50 nM or less, more specifically 40 nM or less, more particularly 30 nM or less, more particularly 20 nM or less and more particularly 10 nM or less.

[85] The term antibody or antigen-binding fragment, as used in this document, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules containing an antigen-binding site that immunologically binds the BSMA antigen. Thus, the term antigen-binding fragments refers to Petition 870190057479, dated 06 / 21 / 2019, pp. 38 / 302 31 / 70 to a fragment of an antibody comprising at least one antigen-binding functional domain. In a particular embodiment, the antigen-binding functional domain comprises the variable domains of the heavy chain according to SEQ ID No. 1 and the light chain according to SEQ ID No. 2 of the J22.9-ISY antibody. Also included are immunoglobulin-like proteins that are selected by means of techniques that include, for example, displaying phages to bind specifically to the BSMA antigen. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass of immunoglobulin molecule.Antibodies and their antigen-bound fragments suitable for use in the present invention include, but are not limited to, polyclonal, monoclonal, monovalent, bispecific, heteroconjugated, multispecific, human, humanized (especially those manufactured in CDR), desimune or chimeric antibodies, single-chain antibodies (e.g., scFv), Fab fragments, F(ab')2 fragments, fragments produced by a Fab expression library, diabodies or tetrabodies (Holliger P. et al., Proc Natl Acad Sci US A. 90 (1993) 6444-8), nanobodies, antiidiotypic (anti-Id) antibodies (including, for example, anti-Id antibodies for antibodies of the invention), and epitope-binding fragments of any of the above.

[86] In some embodiments, the antigen-bound fragments are fragments of human antibodies bound to the antigen of Petition 870190057479, dated 06 / 21 / 2019, pages 39 / 302 32 / 70 of the present invention and include, among others, Fab, Fab' and F(ab')2, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (dsFv) and fragments that include a VL or VH domain. Anti-aggregant antibody fragments, including single-chain antibodies, may include the variable domain(s) alone or in combination with all or part of the following domains: junction region, CL, CH1, CH2 and CH3 domains. Also included in the invention are antigen-linked fragments, also comprising any combination of variable domain(s) with a junction region, CL, CH1, CH2 and CH3 domains. In a particular embodiment, the antibody or antigen-binding fragment thereof comprises a heavy chain constant region that includes a D265C mutation.

[87] The antibodies usable in the invention may be of any animal origin, including birds and mammals. In particular, the antibodies are of human, rodent (e.g., rat, mouse, guinea pig or rabbit), chicken, pig, sheep, goat, camel, cow, horse, donkey, cat or dog origin. It is particularly preferable that the antibodies be of human or murine origin. As used herein, human antibodies include antibodies with the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from transgenic animals for one or more human immunoglobulins and which do not express endogenous immunoglobulins, as described, for example, in U.S. Patent No. 5,939,598 by Kucherlapati & Jakobovits.

[88] In a second aspect, the present invention relates to a Petition 870190057479, dated 06 / 21 / 2019, p. 40 / 302 33 / 70 pharmaceutical composition comprising the conjugate of the present invention.

[89] In a third aspect, the present invention relates to the conjugate of the present invention, or to the pharmaceutical composition of the present invention, for use in the treatment of cancer in a patient, particularly when the cancer is selected from the group consisting of multiple myeloma, diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL), particularly multiple myeloma.

[90] As used herein, treating, treating or treatment of a disease or disorder means performing one or more of the following procedures: (a) reducing the severity of the disease; (b) limiting or preventing the development of symptoms characteristic of the disease(s) to be treated; (c) inhibiting the worsening of symptoms characteristic of the disease(s) to be treated; (d) limiting or preventing the recurrence of the disease(s) in patients who have previously had the disease(s); and (e) limiting or preventing the recurrence of symptoms in patients who were previously symptomatic of the disease(s).

[91] As used in this work, the treatment may comprise administering a conjugate or pharmaceutical composition according to the present invention to a patient, wherein administering includes in vivo administration as well as direct administration to ex vivo tissue, such as venous grafts.

[92] In a particular embodiment, an effective therapeutic amount of the conjugate of the present invention is used.

[93] An effective therapeutic amount is an amount of a Petition 870190057479, dated 06 / 21 / 2019, page 41 / 302 34 / 70 Therapeutic agent is sufficient to achieve the intended objective. The effective amount of a given therapeutic agent will vary depending on factors such as the nature of the agent, the route of administration, the size and species of the animal receiving the therapeutic agent, and the purpose of the administration. The effective amount in each individual case can be determined empirically by a skilled practitioner according to established methods of the art.

[94] In another aspect, the present invention relates to a pharmaceutical composition comprising an amatoxin, according to the present invention, or a conjugate of the present invention of an amatoxin with a target-fixing fraction, further including one or more pharmaceutically acceptable diluents, carriers, excipients, fillers, binders, lubricants, glidants, disintegrants, adsorbents and / or preservatives.

[95] Pharmaceutically acceptable means approved by a federal or state government regulatory agency or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly in humans.

[96] In a particular embodiment, the pharmaceutical composition is used in the form of a systemically administered drug. This includes parenterals, which include, among others, injectables and infusions. Injectable products are formulated in the form of ampoules or as so-called ready-to-use injectable products, for example, ready-to-use syringes or disposable syringes and, in addition, in pierceable vials for Petition 870190057479, dated 06 / 21 / 2019, page 42 / 302 35 / 70 multiple withdrawal. Injectable administration can be via subcutaneous (sc), intramuscular (im), intravenous (iv) or intradermal (ic) injection. In particular, it is possible to produce the respective suitable injection formulations as a crystal suspension, solutions, nanoparticles or colloid-dispersed systems such as, for example, hydrolates.

[97] Injectable formulations can also be produced as concentrates, which can be dissolved or dispersed with aqueous isotonic diluents. Infusion can also be prepared in the form of isotonic solutions, fat emulsions, liposomal formulations and microemulsions. Similar to injectables, infusion formulations can also be prepared in the form of concentrates for dilution. Injectable formulations can also be administered as continuous infusions, both in hospital and outpatient therapy, for example, using mini-pumps.

[98] It is possible to add to parenteral drug formulations, for example, albumin, plasma, expander, surfactants, organic diluents, pH-influencing substances, complexing substances or polymeric substances, in particular as substances that influence the adsorption of the conjugates of the target group toxin of the invention to proteins or polymers, or they may also be added with the aim of reducing the adsorption of the conjugates of the target group toxin of the invention to materials such as injection instruments or packaging materials, for example, plastic or glass. Petition 870190057479, dated 06 / 21 / 2019, page 43 / 302 36 / 70

[99] The amatoxins of the present invention, which constitute a target-binding fraction, can be linked to microcarriers or nanoparticles in parenterals such as, for example, finely dispersed particles based on poly(meth)acrylates, polyacrylates, polyglycols, polyamino acids or polyether urethanes. Parenteral formulations can also be modified as depot preparations, for example, based on the multiple unit principle, if the conjugated toxin of the invention that binds the target group is introduced in a finely dispersed, dispersed and suspended form, respectively, or as a crystal suspension in the medicament, or based on the single unit principle if the target group toxin conjugate of the invention is included in a formulation, for example, in a tablet or rod subsequently implanted.These implants or drug depots in single-unit and multi-unit formulations often consist of so-called biodegradable polymers such as, for example, lactic acid and glycolic acid polyesters, polyether urethanes, polyamino acids, poly(meth)acrylates or polysaccharides.

[100] Adjuvants and carriers added during the production of the pharmaceutical compositions of the present invention formulated as parenterals are particularly aqua sterilisata (sterilized water), pH-influencing substances such as, for example, organic or inorganic acids or bases, as well as their respective salts, buffer substances for adjusting pH values, substances for isotonicity such as, for example, chloride of Petition 870190057479, dated 06 / 21 / 2019, page 44 / 302 37 / 70 sodium, sodium bicarbonate, glucose and fructose, tensors and surfactants, respectively, and emulsifiers such as, for example, partial esters of polyoxyethylene sorbitan fatty acids (e.g., Tween®) or, for example, polyoxyethylene fatty acid esters (e.g., Cremophor®), fatty oils such as, for example, peanut oil, soybean oil or castor oil, synthetic fatty acid esters such as, for example, ethyl oleate, isopropyl myristate and neutral oil (e.g., Miglyol®), as well as polymeric adjuvants such as, for example, gelatin, dextran, polyvinylpyrrolidone, additives that increase the solubility of organic solvents such as, for example, e.g.Propylene glycol, ethanol, N,N-dimethylacetamide, propylene glycol or complex-forming substances such as, for example, citrate and urea, preservatives such as, for example, hydroxypropyl ester of benzoic acid and methyl ester, benzyl alcohol, antioxidants such as, for example, sodium sulfite and stabilizers such as, for example, EDTA.

[101] When formulating the pharmaceutical compositions of the present invention as suspensions in a preferred thickening agent to prevent the binding of toxin conjugates of the target binding portion of the invention or to ensure the resuspension of sediments and / or complex-forming agents such as, for example, EDTA, surfactants and polyelectrolytes are added. It is also possible to achieve complexes of the active ingredient with various polymers. Examples of such polymers are polyethylene glycol, polystyrene, carboxymethylcellulose, Pluronics® Petition 870190057479, dated 06 / 21 / 2019, page 45 / 302 38 / 70 or fatty acid ester with polyethylene glycol / sorbitol. The conjugated toxin of the invention for the target fraction can also be incorporated into liquid formulations in the form of inclusion compounds, for example, with cyclodextrins. In particular, incorporation dispersing agents can be added as additional adjuvants. For the production of lyophilized products, scaffolding agents such as mannite, dextran, sucrose, human albumin, lactose, PVP or gelatin varieties can be used.

[102] EXAMPLES

[103] The invention is explained in more detail by non-limiting examples:

[104] Example 1: Synthesis of HDP 30.2115 Amatoxin ligand

[105] • Antibody-toxin binding can occur with cysteine ​​or lysine residues, a specific marker, or non-natural amino acids of the antibody. In order to obtain homogeneous ADC products with a specific RAD of 2, site-specific conjugation with cysteine ​​in combination with genetically engineered Thiomabs is preferable. The main attributes of the ligand include the requirement to be stable in plasma in order to avoid uncontrolled release of the toxic payload into the circulation, and, on the other hand, the toxin needs to be released inside the cell after internalization of the ADC following target binding. Toxin release inside the target cell can occur through cleavable or non-cleavable ligands. Cleavable ligands can be cleaved from the payload through a variety of mechanisms, including acid degradation as a consequence of a lower pH. Petition 870190057479, dated 06 / 21 / 2019, page 46 / 302 39 / 70 inside the cell compared to circulation and protease cleavage by cathepsin protease B or by thioldisulfide exchange attributed to the more reducing intracellular environment. Non-cleavable ligands require complete lysosomal proteolytic degradation, generating a payload with a charged lysine or cysteine ​​residue of the antibody.

[106] • The main advantage of non-cleavable ligands compared to cleavable ligands is their greater plasma stability. Although it is evident that the activities of ADCs containing non-fermentable ligands are less predictable, cleavable ligands raise concerns regarding non-specific cytotoxicity.

[107] • However, in previous experiments, particularly in vitro experiments, with several different ligands, ADCs containing non-cleavable ligands proved to be less toxic than ADCs with a cleavable ligand, and most amanitin-based ADCs based on cleavable ligands were more effective than non-cleavable ligands. Thus, a removable ligand with cathepsin B was chosen for the drug substance.

[108] The toxin-binding (X-amanineamide HDP 30.2115) is synthesized by a multi-faceted approach using solid-phase peptide synthesis while the bicyclic octapeptide is initially assembled linearly. The starting point is an immobilization of the hydroxyproline resin, followed by a C-terminal coupling of dihydroxyisoleucine (HDP 30.0477). The remaining six amino acids are coupled by the Fmoc strategy. The first cyclization (ring of Petition 870190057479, dated 06 / 21 / 2019, page 47 / 302 40 / 70 right-handed) occurs in the acid cleavage of resin following the Savige-Fontana mechanism. For this to happen, tryptophan is incorporated in its oxidized form, OPI' (HDP 30.0079), as the final amino acid. The second ring is formed by macrolactamization with moderate to high dilution. The linking compound (HDP 30.2109) is synthesized in six linear steps and is finally introduced under standard coupling conditions, after deprotection.

[109] 1. Synthesis of the precursor molecule of synthetic disoxia K

[110] The synthesis of the disoxia K precursor molecule is described in WO 2014 / 009025 in example 5.5. THE HO K

[111] Compound K can be deprotected by treatment with a 7 N NH3 methanol solution (3.0 ml) and agitation overnight.

[112] 2. Synthesis of the synthetic di-deoxy precursor HDP 30.2105

[113] An alternative disoxia precursor molecule comprising a -COOH group instead of the carboxamide group at amino acid 1 can be synthesized (HDP 30.1895) and deprotected to result in HDP 30.2105. Petition 870190057479, dated 06 / 21 / 2019, p. 48 / 302 41 / 70 HDP 30.2105

[114] Step 1: 2-allylic ester of 4-hydroxypyrrolidine-1,2-dicarboxylic acid ester 1-(9H-fluoren-9-ylmethyl) (HDP 30.0013) Com. Source 353.38 C20H19NO5

[115] FmocHypOH (10.0 g, 28.3 mmol) was suspended in 100 ml of 80% MeOH and CS2CO3 (4.6 g, 14.1 mmol) was added. The suspension was stirred at 50°C for 30 minutes until complete dissolution. The reaction mixture was concentrated to dryness and stopped in 100 ml of DMF. Allyl bromide (1.6 ml, 3.6 g, 29.7 mmol) was added dropwise and the reaction was stirred overnight in RT. The DMF was distilled and the residue dissolved in methyl tert-butyl ether. The precipitates were filtered and the clear solution absorbed on Celite anterior column chromatography. The compound was purified on 220 g of n-hexane / ethyl acetate gradient silica gel. Petition 870190057479, dated 06 / 21 / 2019, p. 49 / 302 42 / 70

[116] Yield: 11.5 g, 100%. HDP 30.0013 HDP 30.0400 393.44 393.44 C23H23NO5C73H23NOe ZO XO o Zo Zo ó

[117] Step 2: Resin Loading (HDP 30.0400)

[118] HDP 30,0013 (5.0 g, 14.1 mmol), pyridinium 4-toluenesulfonate (1.33 g, 5.3 mmol) were added to a suspension of 1,3-dihydro-2H-pyrano-2-yl-methoxymethyl resin (5.0 g, 1.0 mmol / g THP-resin) in 40 ml of dichloroethane. The reaction was stirred at 80°C overnight. After cooling, the resin was filtered and extensively washed with dichloroethane, dimethylformamide, acetonitrile, dichloromethane, and methyl tert-butyl ether.

[119] The charge was 0.62 mmol / g (determined by spectroscopy) UV of the methyl fluorene group after deprotection.

[120] Step 3: Solid Phase Precursor Synthesis (HDP 30.1894) HDP 30.0400 393 44 C23H23NO5 1447.69 C74H94N9O19S

[121] Resin pretreatment: Petition 870190057479, dated 06 / 21 / 2019, page 50 / 302 43 / 70

[122] PDS 30.0400 (0.5 g, 0.31 mmol) was treated with N,N-dimethylbarbituric acid (483 mg, 3.1 mmol) and Pd(PPh3)4 (69 mg, 0.06 mmol). The resin was shaken overnight in RT. Subsequently, the resin was extensively washed with dichloromethane, N-methyl-2-pyrrolidone, acetonitrile, dichloromethane and methyl tert-butyl ether and dried under reduced pressure.

[123] Coupling procedure:

[124] All reagents and reagents were dissolved in dichloromethane / N-methyl-2-pyrrolidone containing 1% Triton-X100 (Solvent A).

[125] HDP 30.0477 (257 mg, 0.38 mmol) was dissolved in 3.0 ml of Solvent A and treated with 3.0 ml of a 0.2 N PyBOP solution (333 mg, 0.63 mmol, 2.0 eq), 3.0 ml of a 0.2 N HOBt solution (130 mg, 0.63 mmol, 2.0 eq) and 439 pl DIEA (4.0 eq). The reaction was heated to 50°C for 8 minutes by microwave irradiation (20 W, CEM microwave reactor) and washed with N-methyl-2-pyrrolidone after coupling.

[126] Lack of protection:

[127] Deprotection was performed by adding 6.0 ml of 20% piperidine in N-methyl-2-pyrrolidone at 50°C for 8 minutes. The resin was washed with N-methyl-2-pyrrolidone (Note: No deprotection after coupling of the final amino acid).

[128] All other amino acids were coupled following the above protocol, the weightings are shown below:

[129] 0.63 mmol, 498 mg Fmoc Asp(OAll)OH

[130] 0.63 mmol, 738 mg Fmoc Cys(Tri)OH Petition 870190057479, dated 06 / 21 / 2019, page 51 / 302 44 / 70

[131] 0.63 mmol, 375 mg Fmoc GlyOH

[132] 0.63 mmol, 445 mg Fmoc IleOH

[133] 0.63 mmol, 375 mg Fmoc GlyOH

[134] 0.38 mmol, 242 mg N-Boc-HPIOH (HDP 30.0079)

[135] 4,5-Diacetoxy-2-amino-3-methyl-pentanoic acid; hydrochloride (HDP 30.0477) was synthesized as described in WO 2014 / 009025.

[136] N-Boc-HPIOH (HDP 30.0079) was prepared according to Zanotti, Giancarlo; Birr Christian; Wieland Theodor; International Journal of Peptide & Protein Research, 18 (1981), 162-8.

[137] Step 4: HDP 30.1895

[138] Resin removal and B-ring formation

[139] The resin was stirred with 10 ml of trifluoroacetic acid / dichloromethane 50:50 (v / v) plus 10% methanol for 30 min and finally eluted into a 50 ml flask. The resin was washed twice with methanol (10 ml each time). The combined eluates were concentrated under vacuum and resuspended in 2-4 ml of methanol. The methanolic solution was twice dropped into 50 ml of cold ethyl ether for peptide precipitation. After the Petition 870190057479, dated 06 / 21 / 2019, page 52 / 302 After centrifugation (45 / 70), the precipitate was washed with ethyl ether (twice) and dried under reduced pressure. The white precipitate was solubilized in approximately 4-5 ml of methanol (0.5 ml per 100 mg) and purified by preparative reversed-phase column chromatography. Approximately 100 mg of crude precipitate were purified per run. The fractions were analyzed by mass spectrometry, combined, and distilled with methanol under reduced pressure. The aqueous phase was lyophilized.

[140] Yield: 24.4 mg, 23.7 pmol

[141] Mass spectrometry: [M+H]+, 1030.5

[142] Ring formation in A

[143] The above lyophilized intermediate was dissolved in 25 ml of dimethylformamide and treated with diphenylphosphoryl azide (63 pl, 1185 pmol, 5 eq) and diisopropylethylamine (201 pl, 1185 pmol, 5 eq). The reaction was stirred overnight (20 hours). The conversion was monitored by reverse-phase chromatography and finally cooled with 100 pl of water. The mixture was concentrated by reduced pressure and redissolved in 1-2 ml of methanol. Precipitation of the product was carried out by dropwise addition to 20 ml of ethyl ether. The precipitate was washed twice with ethyl ether and dried under reduced pressure. The next step was carried out without further purification.

[144] Mass spectrometry: [M+Na]+, 1034.6

[145] Ester's lack of protection:

[146] Diethylbarbituric acid (22.3 mg, 118.5 pmol) was added to the crude cyclization product of 2.5 ml of dichloromethane and Petition 870190057479, dated 06 / 21 / 2019, page 53 / 302 46 / 70 Pd(PPh3)4 (27 mg, 23.7 pmol). The reaction was stirred at room temperature overnight. The reaction could be monitored by RP-HPLC. After complete conversion, the mixture was added dropwise to 20 ml of cooled ethyl ether and the precipitate washed twice with ethyl ether. After drying under reduced pressure, the precipitate was dissolved in methanol (1.0 ml) and purified by preparative reverse-phase chromatography.

[147] Yield: 15.0 mg

[148] Mass spectrometry: [M+H]+, 972.3; [M+Na]+, 994.5

[149] Step 5: HDP 30.2105 HDP 30.1895 1012,11 c46h61n9o15s 7N NH3in MeOH RT HDP 30.2105 887.97 θ39^53^9θ13^

[150] HDP 30, 1895 (15.0 mg, 15.3 pmol) was dissolved in 7N methanolic NH3 solution (3.0 ml) and stirred overnight. Conversion was verified by mass spectrometry. After complete conversion, the reaction was concentrated under vacuum, suspended in 80% tert-butanol, and lyophilized. The product was purified by preparative HPLC.

[151] Yield: 12.1 mg

[152] Mass spectrometry: [M+H]+, 888.0; [M+Na]+, 910.2

[153] 3. Synthesis of synthetic dideoxide precursor HDP 30.2115 Petition 870190057479, dated 06 / 21 / 2019, page 54 / 302 47 / 70

[154] A disoxia precursor molecule consisting of a reactive thiol group with a cleavable ligand can be synthesized from the product of example 2 in 7 steps, as follows:

[155] Step 1: Fmoc-Val-OSu (HDP 30.1343) the DSC DIPEA THF L-Valine 339.39 θ20^21^θ4 Fmoc-Val-OSu (HDP 30.1343) 436.47 θ24^24^2θ6

[156] This compound is prepared according to RA Firestone et al, US 6,214,345. Fmoc-Val-OH (20.24 g; 59.64 mmol) and N-hydroxysuccinimide (6.86 g = 1.0 eq.) in tetrahydrofuran (200 ml) at 0°C were treated with N,N'-dicyclohexylcarbodiimide (12.30 g; 1.0 eq.). The mixture was stirred in RT under an argon atmosphere for 6 h, then the solid byproduct dicyclohexyl urea (DCU) was filtered and washed with THF and the solvent was removed by rotavap. The residue was dissolved in 300 ml of dichloromethane, cooled in an ice bath for 6 h and filtered again to Petition 870190057479, dated 06 / 21 / 2019, page 55 / 302 48 / 70 remove the additional DCU. The dichloromethane was evaporated and the solid foam (26.51 g) was used in the next step without further purification.

[157] Step 2: Fmoc-Val-Ala-OH (HDP 30.1414) Fmoc-Val-OSu (HDP 30.1343) 436.47 θ24^24^2θ6 Fmoc-Val-Ala-OH (HDP 30.1414) 410.47 OooHncNoOc zo zo zo

[158] The Step 2 product is prepared in analogy with PW Howard et al. US 2011 / 0256157. A solution of L-alanine (5.58 g; 1.05 eq.) and sodium dicyclohexyl hydrogen carbonate (5.51 g; 1.1 eq.) in 150 ml of water was prepared and added to a solution of HDP 30.1343 (26.51 g; max. 59.6 mmol) in 225 ml of tetrahydrofuran. The mixture was stirred for 50 hours at room temperature. After consumption of the raw material, the solution was divided between 240 ml of 0.2 M citric acid and 200 ml of ethyl acetate. The aqueous layer was separated and extracted with ethyl acetate (3 x 200 ml). The combined organic layers were washed with water and dried brine (300 ml each) (MgSCM) and the solvent was evaporated to approximately 200 ml. The pure product precipitated at this point and was filtered. The mother liquor was evaporated to dryness and the residue was stirred for 1 h with 100 ml of MTBE to obtain additional crystalline material. The two product cultures were combined to 18.01 g (74%) of white powder, (mp: 203-207°C) Petition 870190057479, dated 06 / 21 / 2019, page 56 / 302 49 / 70

[159] MS (ESI+) [M+Na]+found: 410.94; calculated: 411.19 (C23H27N2O5)

[160] [M+Na]+found: 433.14; calculated: 433.17 (C23H27N2O5)

[161] [ 2M+H]+found : 842.70; calculated : 843.36 (C46H52N4NaOio)

[162] Step 3: Fmoc-Val-Ala-PAB-NHBoc (HDP 30.1713) N-(tert.-Butoxycarbonyl)4-aminobenzylamine 222.29 C12H18N2O2 HDP 30.11414 410.47 θ23^26^2θ5 HDP 30.1713 614,75 ^35^42^4^6

[163] The product of phase 2rHDP 30.1414 (1.76 g; 4.28 mmol) and 4 [(N-Boc)aminomethyl]aniline (1.00 g; 1.05 eq.) were dissolved in mL of tetrahydrofuran absc. 2-Ethoxy-N-(ethoxycarbonyl)-1,2-dihydroquinoline (EEDQ 1.11 g; 1.05 eq.) was added and the mixture was stirred at room temperature, protected from light. As the reaction progressed, a gelatinous substance formed from the initially clear solution. After 40 h, the reaction mixture was diluted with 25 mL of methyl tert-butyl ether (MTBE) and stirred for 1 h. The precipitate was then filtered by suction, washed with MTBE, and dried under vacuum to 2.30 g (85% yield) of a white solid.

[164] 1H NMR (500 MHz, DMSO-d6) δ 9.87 (s, 1H) (d, J = 8.2 Hz, 2H), 7.45 - 7.23 (m, 7H), 7.17 (d, J = 8.3 Hz, 2H), 4.44 (p, J = 7.0 Hz, 1H), 4.36 - 4.17 (m, 3H), 3.96 3.89 (m, 1H), 2.01 (hept, J = 6.9 Hz, 1H), 1.39 (s, 9H), 1.31 (d, Petition 870190057479, dated 06 / 21 / 2019, p. 57 / 302 50 / 70 J = 7.1 Hz, 3H) , 0.90 (d, J = 6.8 Hz, 3H) , 0.87 (d, J = 6.8 Hz, 3H) , 0.87 (d, J = 6.8 Hz, 3H) , 3H, 2.01 (hept, J = 6.9 Hz, 1H) , 1.39 (s, 9H) , 1.31 (d, J = 7.1 Hz, 3H) , 0.90 (d, J = 6.8 Hz, 3H) , 0.87 (d, J = 6.8 Hz, 3H).

[165] 13C NMR (126 MHz, DMSO-d6) δ 170.84, 170.76, 156.04, 155.63, 143.77, 143.69, 140.60, 137.41, 134.99, 127.50, 127.26, 126.93, 125.22, 119.95, 118.97, 77.60, 65.62, 59.95, 48.86, 46.62, 42.93, 30.28, 28.16, 19.06, 18.10, 18.03.

[166] Passo 4: H-Val-Ala-PAB-NHBBoc (HDP 30.1747) HDP 30.1713 HDP 30.1747 614,75 392,50 θ35^42^4θ6 θ20^32^4θ4

[167] The HDP 30.1713 compound (1.230 g, 2.00 mmol) from step 3 was placed in a 100 ml flask and dissolved in 40 ml of dimethylformamide (DMF). Diethyl amine (7.5 ml) was added and the mixture was stirred at room temperature. The reaction was monitored by TLC (chloroform / methanol / HOAc 90:8:2). After consumption of the raw material (30 min), the volatiles were evaporated and the residue was co-evaporated with 40 ml of fresh DMF to remove traces of ethyl amine. The crude product was used without further purification for the next step.

[168] MS (ESI+) [MH]+found: 393.26; calculated: 393.25 (C2oH33N404)

[169] [M+Na]+found: 415.35; calculated: 415.23 (C2oH32N4Na04) Petition 870190057479, dated 06 / 21 / 2019, page 58 / 302 51 / 70

[170] [2M+H]+found: 785.37; calculated: 785.49 (CéoHgsNsOs)

[171] Step 5: BMP-Val-Ala-PAB-NHBoc (HDP 30.2108) HDP 30.1747 HDP 30.2108 392.50 543.63 C20H32N4O4 ^27^37^5θ7

[172] The crude product from step 4 HDP 30.1747 (max. 2.00 mmol) was dissolved in 40 ml of DMF, 3-(maleimide)-propionic acid N-hydroxysuccinimide ester (BMPS 532 mg; 1.0 eq.) and Netyldiisopropylamine (510 μL, 1.5 eq.). After consumption of the raw material HDP 30.1747 (TLC: chloroform / methanol / HOAc 90:8:2), the volatiles were evaporated and the residue was stirred with 50 ml of MTBE until a fine suspension was formed (1 h). The precipitate was filtered by suction, washed with MTBE and dried. The crude product (1.10 g) was dissolved in 20 ml of 1:1 dichloromethane / methanol, kieselgur (15 g) was added, and the solvents were removed. The solid material was placed on top of an 80 g silica gel column eluted with a linear gradient of 0-10% methanol in dichloromethane. The product fractions were combined and evaporated to 793 mg (73% in two steps) of amorphous solid.

[173] MS (ESI+) [M+Na]+found: 566.24; calculated: 566.26 (C27H37N5NaO7)

[174] 1H NMR (500 MHz, DMSO-d6) δ 9.75 (s, 1H) , 8.09 (d, J = 7.1 Hz, 1H), 7.98 (d, J = 8.4 Hz, 1H), 7.52 (d, J = 8.6 Hz, 2H), 7,29 - 7,23 (m, 1H), 7,16 (d, J = 8,5 Hz, 2H), 6,98 (s, 2H), 4,39 (p, J = 7,1 Hz, 1H), 4.13 (dd, J = 8,4, 6,7 Hz, 1H) , 4,06 (d, J = 6,1 Petição 870190057479, de 21 / 06 / 2019, pág. 59 / 302 52 / 70 Hz, 2H) , 3, 67 - 3, 56 (m, 2H) , 2,49 - 2,41 (m, 2H) , 1.96 (h, J = 6,8 Hz, 1H) , 1,39 (s, 9H) , 1,30 (d, J = 7,1 Hz, 3H) , 0,86 (d, J = 6,8 Hz, 3H) , 0,82 (d, J = 6,8 Hz, 3H) .

[175] 13C NMR (126 MHz, DMSO-d6) δ 170.80, 170.63, 170.60, 169.72, 155.65, 137.45, 134.94, 134.44, 127.26, 118.95, 77.62, 57.71, 48.92, 42.95, 33.96, 33.64, 30.17, 28.17, 19.02, 18.06, 17.82.

[176] Passo 6: BMP-Val-Ala-PAB-NH2 (HDP 30.2109) £27^37^0? C22H29N5O5 TFA salt: 557,53

[177] O produto HDP 30.2108 (400 mg, 736 pmol) foi dissolvido em 4,000 μL of trifluoroacetic acid was added and stirred for 2 min. Subsequently, the volatiles were evaporated in RT and the residues were co-evaporated twice with 4,000 μL of toluene. The residue was dissolved in 5,000 μL of 1,4-dioxane / water 4:1, solidified in liquid nitrogen and lyophilized: 410 mg (quantity) of colorless powder.

[178] MS (ESI+) [M+Na]+found : 415.35; calc: 466.21 (C22H29N5NaO5)

[179] [2M+H]+found : 887.13; calculated.: 887.44 (C44H59N10O10)

[180] 1H NMR (500MHz, DMSO-d6) 7.34 (m, 2H), 6.98 (s, 2H), 4.39 (p, J = 7.1 Hz, 1H), 4.11 (dd, J = 8.2, 6.6 Hz, 1H), 3.97 (q, J = 5.6 Hz, 2H), 3.69 - 3.58 (m, 2H), 2.49 - 2.40 (m, 2H), 1.96 (h, J = 6.8 Hz, 1H), 1.32 (d, J = 7.1 Petition 870190057479, dated 06 / 21 / 2019, pp. 60 / 302 53 / 70 Hz, 3H), 0.86 (d, J = 6.8 Hz, 3H), 0.83 (d, J = 6.7 Hz, 3H).

[181] 13C NMR (126 MHz, DMSO-d6) δ 171.24, 170.78, 170.72, 169.85, 158.12 (q, J = 33.2 Hz, TEA), 158.25, 157.99, 157.73, 139.19, 134.53, 129.45, 128.52, 119.02, 116.57 (q, J = 296.7 Hz, TFA), 57.78, 49.08, 41.90, 34.00, 33.68, 30.21, 19.07, 18.16, 17.76.

[182] Step 6: HDP 30.2115 HDP 30.2109 TBTU DIEA DMF RT NH HDP 30.2115 O 1313.47 C61H80N14O17S HDP 30.2105 887.97 C39H53N9O13S

[183] ​​HDP 30,2105 (15.0 mg, 16.5 pmol) were treated with 429 μL of a 0.1 M solution of HDP 30,2109 (25.2 pmol, 1.5 eq), 492 μL of 0.1 M TBTU (25.2 μmol, 1.5 eq) and 492 μL of 0.2 M DIEA (49.1 μmol, 3.0 eq) at RT. The reaction was monitored by RP-HPLC. After completion, the reaction was stopped with 100 μL of H2O stirred for 15 minutes and injected into a preparative RP-HPLC.

[184] Yield: 12.2 mg, 56%.

[185] Mass spectrometry: 1313.2 [M+H]+, 1335.5 [M+Na]+

[186] Example 2: Properties of constructions based on HDP 30.2105

[187] Several experiments were carried out to compare the Petition 870190057479, dated 06 / 21 / 2019, page 61 / 302 54 / 70 properties of constructs based on the amanitin derivative dideoxy HDP 30.2105 compared with those of other amanitin variants. The results of these experiments are shown in Figures 2 to 14.

[188] Example 3: Generation and expression of the antibody Thiomab J22.9ISY-D265C

[189] Antibody-ligand and toxin conjugation can occur with lysine or cysteine ​​residues, resulting in a highly variable drug-antibody ratio (DAR). Given that potency and toxicity are strongly influenced by the DAR, homogeneity and comparability of the ADC with the predictable DAR are favorable. Antibodies with engineered reactive cysteine ​​residues (thiomabs) allow for site-specific conjugation and, therefore, the aspartic acid amino acid at position 265 has been replaced by cysteine ​​(D265C). Thus, the resulting antibody variant contains two cysteines introduced into each chain of the Fc region, which serves as a binding site for the toxin-ligand compound and allows the production of ADCs with DAR=2.

[190] Sequence modifications in the Fc region of the antibody can have a dramatic influence on linking antibody-mediated immune responses with the functions of cellular effectors, since residues in the Fc region are responsible for interaction with the IgG Fc receptor (FcR). IgG interactions with FcR play a crucial role in the functions of cellular effectors, including the release of inflammatory mediators, endocytosis of immune complexes, antibody-dependent cellular cytotoxicity (ADCC), and complement-dependent cytotoxicity. Petition 870190057479, dated 06 / 21 / 2019, page 62 / 302 55 / 70 (CDC). Preserving these effector functions in an ADC may contribute to the ADC's antitumor activity. However, this assumption may be incorrect, as these effector functions are generally weak and, more importantly, may compete with ADC internalization, reduce or abolish its toxin-related specific activity, and increase off-target toxicity due to ADC uptake into antigen-negative cells via the Fc receptor. Several CDAs currently in preclinical and clinical development are based on IgG2 and IgG4, which are very inefficient in these effector functions (Trail, 2013; Peters and Brown, 2015).

[191] Detailed mapping of human IgG1 binding sites to FcRI, FcRII, FcRIII and neonatal Fc receptor (FcRn) revealed a crucial role for aspartic acid at position 265. Substitution of aspartic acid in IgG2 and IgG1 completely abolished the interaction with FcR (Baudino et al., 2008; Shields et al., 2001).

[192] The efficiency of antibody-induced effector functions in Trastuzumab (Trademark Herceptin®) and in the corresponding thiomab antibodies with amino acid changes at position 265 (D265C) or 118 (T118C) for control were tested in a THP-1 macrophage cell line. This monocytic cell line expresses multiple FcRs and allows testing of antibody-mediated phagocytosis (Ackerman et al., 2011). Cytotoxicity in THP-1 cells was reduced by at least two orders of magnitude with thiomab D265C compared to thiomab A118C, containing a cysteine ​​mutation at position A118 that did not reduce effector function, and an undeveloped antibody. This reduction effect Petition 870190057479, dated 06 / 21 / 2019, page 63 / 302 The 56 / 70 cytotoxicity with the thiomab modified from amino acid 265 is not due to conjugation of the toxin with artificial cysteine, since, unlike T-D265C-30.1699 which contains a cleavable ligand conjugated with artificial cysteine, in the case of T-D265C30.0643, a stable ligand is conjugated with lysine residues of the antibody. Thus, antibody-dependent effector functions were surprisingly highly reduced due to the D265C substitution in thiomabs (see Table 1).

[193] Table 1. EC50 Compound [M] in THP-1 T-D265C-30.0643 (stable ligand; lysine coupling) 1.9 x 10-8 T-D265C-30.0880 (stable ligand; cysteine ​​coupling) 4.0 x 10-8 T-D265C-30.1699 (cleavable ligand; cysteine ​​coupling) 2.0 x 10-8 T-A118C-30.0643 (stable ligand; lysine coupling) 2.8 x 10-10 T-A118C-30.0880 (stable ligand; cysteine ​​coupling) 7.0 x 10-10 T-A118C-30.1699 (cleavable ligand; cysteine ​​coupling) 4.4 x 10-10 Her-30.0880 (wild type) 4.6 x 10-10 Her-30.0643 (wild type) 1.2 x 10-10

[194] Characterization results of chimeric and sequence-optimized variants of J22.9 revealed improved binding properties of the J22.9-ISY and J22.9-FSY sequence-optimized variants for BCMA compared to J22.9-H, with no obvious difference for the ISYou FSY-variant. Since the use of plasmids expressing the J22.9-ISY antibody variant resulted in improved titers when transiently expressed in cell culture, the J22.9-ISY variant was chosen for conjugation and further evaluation.

[195] The nucleic acid coding sequence for the heavy chain of the J22.9-ISY-D265C monoclonal antibody was obtained from the heavy chain sequence of the humanized J22.9-ISY antibody (see WO 2014 / 068079 and WO 2015 / 166073) as described in WO Petition 870190057479, dated 06 / 21 / 2019, page 64 / 302 57 / 70 2016 / 142049. In addition to the D265C change, J22.9-ISY-D265C also contains an R214K mutation (see SEQ ID No: 1).

[196] To produce the amanitin conjugate J22.9-ISY-D265C30.2115, the J22.9-ISY-D265C antibody was transiently expressed in Expi293FTM cells co-transfected with plasmids for the heavy and light chains. In a further approach, the J22.9-ISY-D265C antibody was produced in CHO cells stably transfected with plasmids expressing both heavy and light chains. The antibody was purified from the cell culture supernatant by protein A chromatography followed by gel filtration. Antibodies produced transiently from Expi293FTM or stable CHO cells show comparable payload conjugation, binding to BCMA, and cytotoxicity in BCMA-expressing cells.

[197] In order to test whether the amino acid exchange in Thiomab J22.9ISY-D265C did not interfere with binding to BCMA, the binding of J22.9-ISY and J22.9-ISY-D265C to BCMA-expressing cells was compared. The binding property of thiomab J22.9-ISY-D265C to BCMA-positive NCI-H929 and MM.1S-Luc was identical to the J22.9-ISY antibody (see Figure 15).

[198] Example 4: Synthesis of the J22.9-ISY-D265C-30.2115 conjugate

[199] HDP conjugation 30.2115 to 10 mg J22.9-ISY-D265C

[200] 10 mg of Thiomab J22.9-ISY-D265C in PBS buffer will be used for conjugation with HDP 30.2115.

[201] Adjust the antibody solution to 1mM EDTA: 2 ml of antibody solution (10.0 mg) + 20 pl 100 mM EDTA, pH 8.0 Amount antibody: 10 mg = 6.8 x 10-8 mol Petition 870190057479, dated 06 / 21 / 2019, p. 65 / 302 58 / 70

[202] Cysteine ​​uncapping by antibody reaction with 40 eq. TCEP:

[203] 2 ml of antibody solution (6.8 x 10-8 mol) + 54.5 μl of 50 mM TCEP solution (2.72 x 10-6 mol)

[204] Incubate for 3 hours at 37°C in a shaker.

[205] Two consecutive dialyses at 4°C in 2.0 l 1x PBS, 1 mM EDTA, pH 7.4 in a Slide-A-Lyzer 20,000 MWCO dialysis cassette, first dialysis ca. 4 h, second dialysis overnight.

[206] Concentrate on approximately 4.0 ml using Ultra Filters Amicon 50'000 MWCO centrifuges.

[207] Antibody oxidation reaction with 20 eq. of dehydroascorbic acid (dhAA):

[208] approx. 2 ml of antibody solution (6.8 x 10-8 mol) + 27.2 μl of fresh 50 mM dhAAA solution (1.36 x 10-6 mol)

[209] Incubate for 3 hours at room temperature in a shaker.

[210] Conjugation with amanitin using 4 eq. HDP 30.2115 and tempering with 25 eq. N-acetyl-L-cysteine:

[211] Solubilize 0.7 mg HDP 30.2115 in 70 μl DMSO = 10 μg / μl

[212] ca. 2 ml of antibody solution (= 9.5 mg; 6.54 x 10-8 mol) + 34.4 μl of HDP 30, 2115 (= 344 μg; 2.62 x 10-7 mol).

[213] Incubate for 1 h at RT.

[214] Tempering by adding 16.4 μl 100 mM of N-acetyl-L-cysteine ​​(1.64 x 10-6 mol).

[215] Incubate for 15 min at room temperature (or overnight at 4°C). Petition 870190057479, dated 06 / 21 / 2019, page 66 / 302 59 / 70

[216] Purify the reaction mixture with lx equilibrated PD-10 columns with 1 x PBS, pH 7.4. Identify the protein-containing fractions with Bradford reagent on parafilm and pool the protein-containing fractions.

[217] Antibody solution dialysis at 4°C overnight in PBS 2.0 l, pH 7.4 and Slide-A-Lyzer 20,000 MWCO Dialysis Cassettes.

[218] Determination of protein concentration by UV spectrum (absorption at 280 nm).

[219] Determination of DAR by LC-ESI-MS-analysis.

[220] Adjust the protein concentration to 5.0 mg / ml (3.4 x 10-5M) and bring to sterile conditions by filtration. Store at 4°C.

[221] Example 5: Characterization of the drug substance J22.9-ISYD265C-30.2115

[222] Production and release tests

[223] To characterize an ADC variant based on HDP 30.2115, it was compared to a variant based on HDP 30.1699 (see Table 1).

[224] HDP 30.1699 Petition 870190057479, dated 06 / 21 / 2019, page 67 / 302 60 / 70

[225] HDP 30.1699 contains naturally sourced amanitin in contrast to the fully synthetic amanitin derivative HDP 30.2115. Due to the chemical synthesis, the following differences exist between the two compounds: HDP 30.2115 contains a thioether bridge and a central tryptophan moiety, while HDP 30.1699 contains a sulfoxide bridge and a 6-hydroxytryptophan moiety. The absence of 6-hydroxytryptophan in HDP 30.2115 requires the antibody to be bound to aspartic acid in contrast to HDP 30.1699 where 6-hydroxytryptophan is used for binding. A cleavable cathepsin B ligand was used in both compounds.

[226] The antibody J22.9-ISY-D265C was conjugated to compounds HDP 30.1699 and HDP 30.2115 using maleimide-chemistry as described above and tested for aggregates, DAR and product quality by analytical SECHPLC, mass spectrometry, SDS-Page and Western Blot.

[227] The results of the tests for categories B16-0040 and B160049 are presented as examples in figure 16.

[228] The stability of J22.9-ISY-D265C-30.2115 and J22.9-ISY-D265C30.1699 was tested after incubation at 37°C for 0, 4, and 10 days in PBS, human, cynomolgus, or rat plasma. In contrast to J22.9ISY-D265C-30.1699, Western Blot analyses surprisingly revealed a particularly high stability over the time of the experiment for J22.9-ISY-D265C-30.2115 in PBS or plasma (see Figure 17). Thus, the ADC containing the synthetic amanitin derivative showed superior stability to the ADC with naturally sourced amanitin.

[229] The plasma stability of both variants of ADC was Petition 870190057479, dated 06 / 21 / 2019, page 68 / 302 61 / 70 confirmed in a cytotoxicity assay based on BCMA-positive NCIH92 cells (see Table 2) after incubation for 0, 4, and 10 days in PBS, human, cynomolgus, or mouse plasma. Incubation in PBS or plasma for up to 10 days has almost no influence on the cytotoxic potential of J22.9-ISY-D265C-30.2115. In contrast, the cytotoxicity and therefore the stability of J22.9ISY-D265C-30.1699 was clearly reduced after incubation in human, cynomolgus, or mouse plasma, as already observed in Western Blot analyses (see Figure 18).

[230] Table 2. EC50 human plasma cynomolgus plasma rat plasma PBS pH 7.4 J22.9ISYD265C- day 0 2.8 x 10-10 2.5 x 10-10 1.2 x 10-10 2.4 x 10-10 day 4 2.7 x 10-10 2.5 x 10-10 1.8 x 10-10 2.4 x 10-10 30.2115 day 10 1.0 x 10-9 2.9 x 10-10 6.0 x 10-10 4.1 x 10-10 J22.9ISYD265C- day 0 1.8 x 10-10 2.0 x 10-10 8.6 x 10-11 1.6 x 10⁻¹⁰ day 4 3.7 x 10⁻⁷ 2.1 x 10⁻⁹ 2.0 x 10⁻⁹ 3.6 x 10⁻¹⁰ 30.1699 day 10 6.0 x 10⁻¹⁰

[231] The cytotoxicity potentials of both ADCs were tested in five BCMA-positive MM cell lines (NCIH929, MM.1S Luc, MM.1S, U266B1, and OPM-2) and one BCMA-negative control cell line (CCRF-CEM). Both ADCs showed high cytotoxic activity in the picomolar range with slightly higher toxicity than J22.9-ISY-D265C-30.1699 in some cell lines. The cytotoxicity of J22.9-ADCs is strongly dependent on BCMA expression levels on the cell surface, with no toxicity observed in non-BCMA expression control cells. Furthermore, both amanitin-ADCs showed low EC50 values ​​in OPM-2 cells that correlate with poor BCMA expression (see Petition 870190057479, dated 06 / 21 / 2019, page 69 / 302 62 / 70 Table 3 / Figure 19 and Table 4 / Figure 20).

[232] Table 2. Cell line CD269 protein (Western blot) CD138 protein (Western blot) J22.9ISY binding (FACS) +++ ++ Multiple myeloma cell (B lymphoblasts) established from MM.1S bone marrow from a man ++ 55-year-old with relapsed plasmacytic leukemia after chemotherapy MM.1S Luc MM.1S cells expressing luciferous ++ NCIH929 Multiple myeloma cell (B lymphoblasts) established in a 62-year-old white woman with relapsed multiple myeloma +++ U266B1 Multiple myeloma cell (B lymphoblasts) derived from the peripheral blood of a 53-year-old patient with IgE ++ multiple myeloma OPM-2 Multiple myeloma cell (B lymphoblasts) established from the peripheral blood of a 56-year-old woman with leukemic phase (relapsed, terminal) multiple myeloma (IgG lambda) + KMS-11 Multiple myeloma cell (B lymphoblasts) established from a patient with multiple myeloma + RPMI8226 Multiple myeloma cell (B lymphoblasts) established from peripheral blood from a 61-year-old man with multiple myeloma + / - CCRFCEM. T-lymphoblastoid cell line established from the peripheral blood of a 3-year-old white girl with acute lymphoblastic leukemia (ALL). +++ ++ ++ +++ +++ + +++ + + / - + + + Petition 870190057479, dated 06 / 21 / 2019, page 70 / 302 63 / 70 in relapse (control cell line)

[233] Table 4. EC50 [M] : NCI-H929 MM.1S Luc MM.1S U266B1 OPM-2 J22.9-ISY- D265C30.1699 7.0 x 10-11 6.5 x 10-11 1.7 x 10-10 7.3 x 10-11 7.9 x 10-9 J22.9-ISY- D265C30.2115 9.7 x 10-11 2.3 x 10-10 2.9 x 10-10 1.4 x 10-10 1.4 x 10-7

[234] Example 6: In vivo pharmacological activity in the model of Multiple Myeloma Xenograft

[235] 1. Subcutaneous Xenograft Model

[236] Individual dosage

[237] The antitumor activity of J22.9-ISY-D265C-30.2115 and J22.9- ISY-D265C-30.1699 was tested in a subcutaneous NCI-H929 mouse xenograft model (see Table 3 for cell line details).

[238] Single treatment with doses of 2 mg / kg resulted in an initial response followed by tumor regrowth in 7 of 8 mice for J22.9-ISY-D265C-30.1699 and 6 of 8 mice for J22.9-ISY-D265C-30.2115. At doses of 4 mg / kg, complete tumor remission was achieved in 8 of 8 mice for J22.9ISY-D265C-30.1699 and 7 of 8 mice for J22.9-ISY-D265C30.2115 and the mice remained tumor-free for more than 100 days (the time course of the experiment). At doses of 2 mg / kg, J22.9-ISY-D265C-30.2115 showed slightly superior antitumor efficacy compared to J22.9-ISY-D265C-30.1699. There was no statistically significant reduction in body weight, except for J22.9-ISY-D265C-30.1699 at doses of 4 mg / kg (see Figure 21).

[239] Repeated Dosage

[240] The efficacy of the medicinal substance J22.9-ISY-D265C Petition 870190057479, dated 06 / 21 / 2019, page 71 / 302 64 / 70 30.2115 was evaluated in a repeated-dose adjustment in the NCI-H929 subcutaneous xenograft model. Compared to the single-dose application described above, doses were reduced to 1, 0.5, and 0.25 mg / kg and applied once weekly (1x / week), every two weeks (1x / 2 weeks), or every three weeks (1x / 3 weeks). Repeatedly applied doses of 1 mg / kg resulted in tumor regression, and with repeated doses of 2 mg / kg, complete tumor remission was observed (see Figure 22).

[241] 2. Intravenous Xenograft Model

[242] Individual dosage

[243] The antitumor activity of J22.9-ISY-D265C-30.1699 and J22.9ISY-D265C-30.2115 was tested in an intravenous dissemination MM.1S Luc xenograft model at doses of 2 and 4 mg / kg. Both compounds showed very effective and comparable antitumor activity, with complete tumor remission for more than 100 days (see Figure 23A). Only 1 in 10 mice for both compounds showed slight tumor regrowth after initial response for more than 90 days (see Figure 23B).

[244] In the MM.1S dissemination model, the Luc xenograft model doses of the pharmaceutical substance J22.9-ISY-D265C-30.2115 were further reduced for single-dose application of 1, 0.3, and 0.1 mg / kg. A single dose of 0.3 mg / kg resulted in complete eradication of the tumor (see Figure 24).

[245] Example 7: Non-human primate (NHP) tolerance study

[246] J22.9-ISY-D265C-30.2115 and J22.9-ISY-D265C-30.1699 were Petition 870190057479, dated 06 / 21 / 2019, page 72 / 302 65 / 70 animals were evaluated for a dose-escalation tolerability study in cynomolgus monkeys. Groups of 3 animals were injected with J22.9ISY-D265C-30.1699 on days 1 (0.3 mg / kg), 22 (1 mg / kg), and 44 (3 mg / kg), or with J22.9-ISY-D265C-30.2115 on days 1 (0.3 mg / kg), 21 (1 mg / kg), and 42, 64, 84, and 106 (3 mg / kg each time point). Animals were monitored over time for biochemical and hematological blood parameters (see Figure 25), urinalysis, body weight, food consumption, clinical signs, and mortality. In addition, blood samples were collected for pharmacokinetic studies. At the end of the experiments, tissue samples were used for histopathological examination.

[247] Doses up to 3 mg / kg of both compounds were well tolerated, with no signs of renal injury as serum parameters, body weight and food intake were unaffected. Doses of 3 mg / kg resulted in increased, but transient, levels of liver enzymes (ALT, AST) and the nonspecific inflammatory marker LDH. Repeated dosing of 3 mg / kg of J22.9-ISY-D265C-30.2115 did not result in further increases in liver enzymes or LDH.

[248] Example 7: Cytotoxic potential of J22.9-ISY-D265C-30.2115 compared with the F derivative of monomethyl auristatin.

[249] The cytotoxicity potentials of J22.9-ISY-D265C-30.2115 were compared with the interchain conjugate J22.9-ISY-MMAF in two BCMA-positive MM cell lines (MM.1S Luc and KMS-11). Both ADCs showed high cytotoxic activity in the picomolar range after 96h with slightly higher toxicity than J22.9-ISY-MMAF (see Figure 26A). The efficacy of both compounds was compared Petition 870190057479, dated 06 / 21 / 2019, page 73 / 302 66 / 70 in a timeline experiment on the two cell lines. Cytotoxicity was measured after 24, 46, 72, 96, and 120 hours (see Figures 26B + 26C). J22.9-ISY-D265C-30.2115 unfolded full cytotoxicity after 96 and 120 hours, while the MMAF conjugate showed a full cytotoxic potential after 48 and 72 hours. This indicates that the amanitin derivative needs more time to develop its cytotoxic potential and drive cells to apoptosis due to its mode of action than MMAF.

[250] Example 8: Efficacy of J22.9-ISY-D265C-30.2115 in a diffusion xenograft model

[251] The antitumor activity of J22.9-ISY-D265C-30.2115 was compared to the interchain conjugate J22.9-ISY-MMAF in an intravenous MM.1S Luc xenograft model at doses of 1 and 4 mg / kg. The MMAF conjugate showed a very rapid initial response after five days at both doses and tumor regrowth after 20 and 50 days, respectively. J22.9-ISY-D265C-30.2115, in contrast, showed a slower initial response after 10 days at both doses, but a longer period until tumor regrowth after 50 and 100 days, respectively (see Figure 27). Thus, the amatoxin conjugate showed better efficacy in terms of tumor-free survival, despite its slower onset of action (see Figures 26(A) to (C)).

[252] References

[253] Ackerman ME et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods. 2011 Mar 7; 366(1-2): 8—19. Petição 870190057479, de 21 / 06 / 2019, pág. 74 / 302 67 / 70

[254] Baudino L et al. Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions. J Immunol. 2008 Nov 1;181(9):6664-9.

[255] Belucci R et al. Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood. 2005 May 15;105(10):3945-5

[256] Bird JM et al. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol. 2011 Jul;154(1):32-75

[257] Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol. 2006 Oct;18(5):263-75

[258] Chesi M, Bergsagel PL. Advances in the pathogenesis of multiple myeloma. Int J Lab Hematol. 2015 May;37 Suppl 1:108-14

[259] Davis MB, Preston JF. A Conjugate of α -amanitin and Monoclonal Immunoglobulin G to Thy 1.2 Antigen is Selectively Toxic to T Lymphoma Cells. Science 213 (1981) 1385-1388

[260] Dimopoulos MA et al. Current treatment landscape for relapsed and / or refractory multiple myeloma. Nat Rev Clin Oncol. 2015 Jan;12(1):42-54

[261] Dimopoulos MA et al. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia. 2008 Aug;22(8):1485-93

[262] Hayes JM et al. Glycosylation and Fc receptors. Curr Top Microbiol Immunol. 2014;382:165-99

[263] Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest. 2012 Petição 870190057479, de 21 / 06 / 2019, pág. 75 / 302 68 / 70 Oct;122(10):3456-63

[264] Leukemia. 2009 Jan;23(1):3-9

[265] Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004 Oct 28;351(18):1860-73.

[266] Marino SF, Olal D, Daumke O. A complex water network contributes to high-affinity binding in an antibody-antigen interface. Data Brief. 2015 Dec 19;6:394-7

[267] Morris PW, Venton DL. Regiospecific amine substitution into □-amanitin with retention of inhibitory properties against eukaryotic class II RNA polymerase. Int. J. Peptide Protein Res. 21 (1983) 419-430

[268] Oden et al. Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma. Mol Oncol. 2015 Aug;9(7):1348-5

[269] Peters C, Brown S. Antibody-drug conjugates as novel anticancer chemotherapeutics. Biosci Rep. 2015 Jun 12;35(4).

[270] Rajkumar SV et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 Nov;15(12):e538-4

[271] Rickert RC et al. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev. 2011 Nov;244(1):115-33

[272] Sanchez et al.Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 2012 Sep;158(6):727-38

[273] Shaffer AL et al. IRF4 addiction in multiple myeloma. Petição 870190057479, de 21 / 06 / 2019, pág. 76 / 302 69 / 70 Nature. 2008 Jul 10;454(7201):226-31

[274] Shields RL et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2001 Mar 2;276(9):6591-604

[275] Trail PA. Antibody drug conjugates as cancer therapeutics. Antibodies 2013, 2(1), 113-129.

[276] Wieland T, Faulstich H. Amatoxins, phallotoxins, phallolysin, and antamanide: the biologically active components of poisonous Amanita mushrooms. CRC Crit Rev Biochem. 1978 Dec;5(3):185-260

[277] Zhao L, May JP, Blanc A, Dr. Dietrich DJ, Loonchanta A, Matinkhoo K, Pryyma A, and Perrin DM. Synthesis of a Cytotoxic Amanitin for Biorthogonal Conjugation. ChemBioChem 16 (2015) 14201425

[278] Sequências:

[279] Humanizado J22.9 cadeia pesada J22.9-ISY-D265C (SEQ ID N°: 1):

[280] EVQLVESGGG LVQPGGSLRL SCAASGFTFS RYWISWVRQA PGKGLVWVGE TAVYYCASLY GTAALGCLVK VPSSSLGTQT PSVFLFPPKP KTKPREEQYN KAKGQPREPQ INPSSSTINY YDYGDAYDYW DYFPEPVTVS YICNVNHKPS KDTLMISRTP STYRVVSVLT VYTLPPSREE APSLKDKFTI GQGTLVTVSS WNSGALTSGV NTKVDKKVEP EVTCVVVCVS VLHQDWLNGK MTKNQVSLTC SRDNAKNTLY ASTKGPSVFP HTFPAVLQSS KSCDKTHTCP HEDPEVKFNW EYKCKVSNKA LVKGFYPSDI LQMNSLRAED LAPSSKSTSG GLYSLSSVVT PCPAPELLGG YVDGVEVHNA LPAPIEKTIS AVEWESNGQP Petition 870190057479, dated 06 / 21 / 2019, page 77 / 302 70 / 70 ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV QKSLSLSPGK

[281] Humanized J22.9 light chain (SEQ ID N°: 2):

[282] EIVMTQSPAT LSVSPGERAT LSCKASQSVE GQAPRALIYS ASLRFSGIPA RFSGSGSGTE FTLTISSLQS YNNYPLTFGA GTKLELKRTV AAPSVFIFPP SDEQLKSGTA PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT VYACEVTHQG LSSPVTKSFN RGEC MHEALTHYT SNVAWYQQKP EDFAVYYCQQ SVVCLNNFY LSKADYEKHK Petition 870190057479, dated 06 / 21 / 2019, p. 78 / 302

Claims

1 / 2 CLAIMS 1. Amanitin conjugate, according to Formula I, comprising: a) an amatoxin; b) a BCMA-binding group, comprising (i) the variable domains of the heavy chain according to SEQ ID No. 1 and the light chain according to SEQ ID No. 2 of the J22.9-ISY antibody and (ii) a constant region of the heavy chain comprising a D265C mutation; and, (c) a protease-cleavable linker, characterized in that said BCMA-binding moiety is linked to said linker through the thiol group of the cysteine ​​residue at position 265 of the antibody heavy chain; said amatoxin includes (i) an amino acid 4 with a 6'-deoxygenating position; and (ii) an amino acid 8 with an S-deoxygenating position. Formula I 2. Amanitin conjugate, according to claim 1, characterized in that said BCMA-linking group comprises the heavy chain according to SEQ ID No. 1 and the light chain according to SEQ ID No.

2.

3. 0 amanitin conjugate, according to claim 1 or 2, characterized by the fact that the aforementioned Petition 870260089094, dated 08 / 31 / 2026, page 12 / 13 2 / 2 obligatory fraction of BCMA is an IgG1.

4. The amanitin conjugate, according to any one of claims 1, 2 or 3, characterized in that the conjugate comprises a pharmaceutical composition.

5. The amanitin conjugate, according to any one of claims 1, 2, 3 or 4, characterized in that the conjugate is used in the treatment of cancer in patients, particularly when the cancer is selected from the group consisting of multiple myeloma, diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL), particularly multiple myeloma. Petition 870260089094, dated 08 / 31 / 2026, page 13 / 13